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1. Abstract
Recent bioinformatic studies have shown that quadruplex-forming sequences occurs with a high 
frequency  in  gene  promoter  regions,  upstream  of  the  Transcription  Start  Sites  (TSS).  This 
important  finding has raised the question whether  quadruplexes represent structural  elements 
playing a role on transcription regulation. To address this question our laboratory focused on 
HRAS and  KRAS genes  as  their  promoters  contain  G-rich  elements  that  can  fold  into 
quadruplexes. 
An insight into the structure of the  RAS quadruplexes has been obtained by circular dichroism 
(CD) and DMS-footprinting assays. Additionally, we found that the RAS quadruplexes are bound 
by transcription factors such as MAZ and Sp1 and that protein hnRNP A1 is able to unfold the 
KRAS quadruplex. To investigate on the role played by quadruplex DNA, we engineered reporter 
plasmids  in  which  quadruplex-forming  sequences  were  either  wild-type  or  mutated. 
Transcription data were also obtained with cells treated with small molecules, such as cationic 
porphyrins  and guanidinio  phthalocyanines,  that  stabilize  quadruplexes.  Together  our  results 
allowed us to suggest for the first time a transcription mechanism for the HRAS proto-oncogene, 
according to which quadruplex DNA behaves as a repressor element of transcription.
From this model we developed a decoy strategy to inhibit KRAS or HRAS transcription in cancer 
cells. This strategy is based on the use of chemically modified oligonucleotides (this task has 
been carried  out  in  collaboration  with  Prof.  Erik  Pedersen  from the  University  of  Southern 
Denmark, Odense) that mimic the RAS quadruplexes which are formed in the critical promoter 
regions. Upon introduction in the cells, the decoys should bind to MAZ and Sp1 and deprive 
these promoters of their natural transcription factors. As the RAS gene give to cells a mitogenic 
signal, the decoys, developed in the course of this PhD, showed to be powerful antiproliferative 
agents with a potential in cancer therapy either to directly cure cancer or to sensitize cancer cells  
to conventional treatments. Work has been directed towards the elucidation of the mechanism of 
cell death caused by the decoys. 
This study is the starting point of a new anticancer therapy against the tumours bearing mutant 
RAS alleles.       
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2. Introduction
2.1. Quadruplex DNA
In 1910, Bang reported that concentrated solutions of guanylic  acid formed a gel. In fact 
concentrated solution of about 25 mg/ml of guanylic acids at pH 5 are extremely viscous and,  
if  cooled,  form  a  clear  gel.  From  examination  of  the  optical  properties  of  the  gel  and 
investigation of the structure of fibres obtained from the gel drying, at least in the case of 5’ 
isomers, the phenomenon may be explained as being due to helix formation by the guanylic 
acid (Gellert M et al. 1962). Even if this inclination of guanine-rich oligonucleotides to form 
polymers has been recognized for nearly forty years, the level of interest in the structure that 
these G-rich sequences can adopt, has increased markedly in the past three decades to date 
(Keniry MA 2001). The molecular basis for the association was subsequentially determined 
by  fibre  diffraction  and  biophysical  studies  using  the  concept  that  Hoogsteen  hydrogen-
bonded guanine-tetrad is the basic structural motif (Burge S et al. 2006). 
These structures are variously referred to as G4-DNA, quadruplexes, G-quadruplexes and G-
tetraplexes. Quadruplexes can be made from one to four strand of guanines. In the first case 
they are called intramolecular quadruplexes while in the others they are called intermolecular 
quadruplexes. Especially in intramolecular quadruplexes, four runs of two or three guanines 
are separated by short sequence that create loops into the structure (Figure 1). 
Figure 1
Maizels N Dynamic roles for G4 DNA in the biology of eukaryotic cells. Nature Structural & Molecular Biology 2006, 13, 1055-1059
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A quadruplex  is  stabilized  by  G-quartets,  planar  arrays  of  four  guanines  in  which  each 
guanine pairs with two neighbours by Hoogsteen bonding. Basically the quadruplex itself 
consists of multiple vertically stacked guanine tetrads. Hoogsteen hydrogen bonds between 
the N12, N7, O6 and N2 guanine bases associate each of the four guanines to form a planar G-
tetrad (Figure 2). 
Figure 2 
Maizels N Dynamic roles for G4 DNA in the biology of eukaryotic cells. Nature Structural & Molecular Biology 2006, 13, 1055-1059
The involvement of N7 of guanines in the Hoogsteen base-pairing of a quadruplex protects the 
site from chemical modification, such as methylation by dimethyl sulfate (DMS). This unique 
feature makes it possible to distinguish a quadruplex structure from single-strand or B-form 
duplex DNA by DMS footprinting (Qin Y et al. 2008). 
Each tetrad forms a central core, comparable in size to a heme moiety, which is encircled by 
four  phosphodiester  backbones  (Maizels  N  2006).  The  formation  and  stability  of 
quadruplexes is monovalent cation-dependent. This has been ascribed to the strong negative 
electrostatic potential created by the guanines O6 oxygen atoms, which form a central channel 
of the G-tetrad stacked with the cation located within this channel. The precise location of the 
cations between the tetrads is dependent on the nature of the ion, with Na+ ions within the 
channel being observed in a range of geometries; in some structures a Na+ ion is in plane with 
a G-tetrad whereas in other it is between two successive G-tetrads (Figure 3). K+ ions are 
always equidistant between each tetrad plane and from the eight oxygen atoms in a symmetric 
tetragonal  bipyramidal  configuration  (Burge  S  et  al.  2006).  In  fact  quadruplexes  form 
spontaneously in physiological salts. They are stabilized by K+ at concentration far below the 
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levels typical of mammal cells (140 mM). As might be expected, intramolecular quadruplex 
formation occurs in a concentration-independent manner, whereas high DNA concentrations 
accelerate intermolecular quadruplex formation (Maizels N 2006). 
Figure 3
Keniry MA Quadruplex structures in nucleic acids. Biopolymers 2001, 56, 123-146
As mentioned above quadruplexes can be formed from one, two or four separate strands of 
DNA and can display a  wide variety of topologies,  which are in  part  a  consequences  of 
various  possible  combinations  of  strand polarities,  as  well  as  variations  in  loop size  and 
sequence.  When  the  four  guanine  strands  are  all  parallel  the  structure  is  called  parallel 
quadruplex. Strands in such fashion require a connecting loop to link the bottom G-tetrad 
with the top G-tetrad, leading to propeller type loops (Figure 4c). This feature has been found 
in crystal  structures and in solution for quadruplexes formed from human telomeric DNA 
sequences. 
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Edge-wise or lateral loop Diagonal loop
V-shaped loopDouble-chain reversal or propeller loop
Figure 4
Patel DJ Human telomere, oncogenic promoter and 5’-UTR G-quadruplexes: diverse higher order DNA and RNA targets for cancer 
therapeutics Nucleic Acids Research, 2007, Vol. 35, No 22 7429-7455
Quadruplexes are designated as anti-parallel  when at least  one of the four strands is anti-
parallel to the others. This type of topology is found in the majority of bimolecular and in 
many unimolecular quadruplex structures determined to date. In these structures two further 
types of loops have been observed. The first type is called lateral (sometimes termed edge-
wise) loop and joins adjacent G-strands (Figure 4a). Intramolecular quadruplexes with three 
lateral loops or edge-wise (Figure 4a) are frequently referred to as chair structures (Keniry 
MA 2001). Two of these lateral loops can be located either on the same or opposite faces of a 
quadruplex, corresponding to head-to-head or head-to-tail respectively when in bimolecular 
quadruplexes.  The second type  of anti-parallel  loop, the diagonal  loop, joins  opposite  G-
strands (Figure 4b).  In this  instance the directionalities  of adjacent  strands must  alternate 
between parallel and anti-parallel, and are arranged around a core of four stacked G-tetrads.
All parallel quadruplexes have all guanine glycosidic angles in an  anti  conformation. Anti-
parallel quadruplexes have both syn and anti guanines (Figure 5), arranged in a way that is 
particular  for  a  given topology and set  of  strand orientations,  having the  four  strands in 
differing positions relative to each other (Burge S et al. 2006).
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Figure 5
Francis SH, Blount MA, et al. Mammalian Cyclic Nucleotide Phosphodiesterases: Molecular Mechanisms and Physiological Functions 
Physiol. Rev. 2011,  91, 651–690
All  quadruplex  structures  have  four  grooves,  defined  as  the  cavities,  bounded  by  the 
phosphodiester  backbones.  Grooves  dimensions  are  variable  and  depend  on  the  overall 
topology and the nature of the loops. Grooves in quadruplexes with only lateral and diagonal 
loops are structurally simple and the walls of these grooves are bounded by monotonic sugar 
phosphodiester  groups.  In  contrast,  grooves  that  incorporate  propeller  loops  have  more 
complex structural features that reflect the insertion of the variable sequence loop into the 
grooves. 
Quadruplexes composed of a single dGn strand almost invariably form right-handed parallel 
structures  that  contain  the  bases  in  the  anti conformation.  The  four  strands  are  oriented 
parallel  to  each  other  and  consequently  all  the  four  grooves  in  these  quadruplexes  are 
identical.  Quadruplexes  formed  from  double  dGn repeats  tend  to  assemble  into  dimeric 
structures by the association of a pair of hairpins (Keniry MA 2001) (Figure 6B-F).
“Tesi di dottorato di Alexandro Membrino, discussa presso l’Università degli Studi di Udine”
Figure 6
Keniry MA Quadruplex structures in nucleic acids. Biopolymers 2001, 56, 123-146
 
2.1.1. Quadruplex motifs in the human genome
Intramolecular  quadruplexes formed by a single DNA strand have attracted much interest 
because they might form in telomeres, oncogene promoter sequences and other biologically 
relevant regions of the genome (Bates PJ et al. 2007). Quadruplex-forming sequences have 
been found in different genomes: from bacterial to human. Analysis of more than 61000 gene 
sequences across 18 prokaryotes show enrichment of quadruplex motifs in regulatory regions 
and  indicate  their  predominance  within  promoters  of  genes  pertaining  to  transcription, 
secondary metabolite biosynthesis and signal transduction. Quadruplex DNA may represent a 
regulatory signal. This is supported by the conservation of quadruplex motifs in promoters of 
orthologous genes across phylogenetically related organisms (Rawal P et al. 2006). Even in 
the  yeast  genome it  is  possible  to  find  strong enrichment  of  sequences  able  to  fold into 
quadruplex  structures  in  upstream  promoter  regions,  as  well  as  weaker  but  significant 
enrichment  in open reading frames (Hershman SG et al.  2008). In higher eukaryotes  it is 
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possible to find quadruplex-forming sequences. Analysing and comparing the distribution of 
quadruplex  motifs  in  genomic  regions  flanking  the  transcription  start  sites  of  13  animal 
species  suggested  an  extensive  selection  for  quadruplex  enrichment  in  transcriptional 
regulatory regions of warm-blooded animals (Zhao Y et al 2007).
The  specific  location  and  conservation  of  G-rich  sequences  in  genomes  from  different 
procaryotes  and eukaryotes  indicates  a  strong selective  pressure to  retain  the quadruplex-
forming potential.  A reason for  this  could  be that  the regulated  formation  of  quadruplex 
structures provides an elegant nucleic-acid-based mechanism for modulating transcription and 
translation. The formation of quadruplexes during replication could well provide an additional 
level of replication control or a connection to a cell-cycle checkpoint (Todd AK 2007). 
For these reasons lot of efforts have been done to understand the localization and abundance 
of potentially quadruplex-forming sequences throughout the human genome.
Quadruplex  motifs  are  present  in  the  human  genome  with  an  average  incidence  of  ~1 
quadruplex every 10000 bases (Lipps HJ et  al.  2009).  Using computational  methods it  is 
possible to map quadruplex motifs in gene promoters that may be involved in transcription 
regulation.  Quadruplex were found to be highly prevalent  in human gene promoters.  The 
analysis  revealed  evidence  of  evolutionary  selection  pressure  to  concentrate  quadruplex 
elements in gene promoters and proximal to the TSS of genes. 
Promoter  quadruplexes  were  also  found to be  strongly associated  with the  open form of 
chromatinised DNA as judged by experimental genome-wide nuclease hypersensitive data. 
Quadruplex loops are critical to the stability of folded structure and promoters quadruplexes 
show an enrichment of stabilizing loops that define a precise fold (Lipps HJ et al. 2009). 
Putative Quadruplex Sequences (PQS) are enriched by a factor of 6.4 in gene promoters as 
compared  to  the  average  throughout  the  whole  human  genome.  Observation  rising  from 
computational analysis is that 42.7% of gene promoters contained at least one PQS. Within 
promoters the chance to find a PQS is directly related to its proximity with the TSS. The 
highest concentration of PQS occurs very near the TSS, with the PQS density in the first 100 
upstream bases being over 12 times higher than the genome average (Lipps HJ et al. 2009) 
(Figure 7).
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Figure  7
Huppert JL, Balasubramanian S G-quadruplexes in promoters throughout the human genome Nucleic Acids Research 2007, 35, 406-413
Genomic analyses can identify sequences in living cells with PQS using algorithms based on 
analysis of structures formed by synthetic oligonucleotides in vitro.
To understand how PQS are located into the human genome some software-based quadruplex 
search start from a simple folding rule (Huppert JL et al. 2005) describing sequences that may 
form quadruplexes.
Sequence searches may be used to locate potential quadruplex-forming sequences. However 
to determine whether they fold into a real quadruplex experimental evidences is required. The 
current search patterns are usually based on telomeric-like quadruplex topologies and are a 
useful way to determine the location of quadruplex sequences. However they may miss a 
number of quadruplex structures which do not follow the conventional pattern of four guanine 
runs (Huppert JL et al. 2007). Algorithms typically search for the presence of four run of at  
least three guanines within a window 40-100 nucleotides in length, sufficient for quadruplex 
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formation within synthetic oligonucleotides. Quadruplexes are dynamic structures and their 
formation depends on denaturation of the duplex, as occurs during replication, transcription or 
recombination (Maizels N 2006). It is important to emphasize that algorithms can establish 
the  potential  to  form this  conformation,  because  most  genomic  DNA is  maintained  as  a 
Watson-Crick duplex, in which G-C pairing prevents formation of quadruplex. 
Four aspects are usually considered in developing this kind of rule: a. strand stoichiometry; b. 
the  number  of  stacked  tetrads  in  the  quadruplex  core;  c.  the  presence  of  mutations  or 
deletions; and d. the length and composition of loops. This rule predicts sequences that could 
form a quadruplex, but does not preclude the possibility of some or all of the motifs forming 
an alternate structure. 
For  what  concern  the  stoichiometry  one  should  consider  that  since  under  physiological 
conditions the strand concentration of DNA is relatively low (in the order of nM), except in 
rare cases, interstrand quadruplexes will be strongly disfavoured. Single G-tetrads have only 
been  reported  in  highly  concentrated  guanine  solutions  at  mM  concentrations,  and  are 
unlikely  to  be  physiologically  relevant.  There  are  a  few  examples  of  double-stack 
quadruplexes, such as thrombin-binding aptamer and the sequences identified as responsible 
for the fragile X sindrome (Weisman-Shomer P et al. 2000). 
Furthermore an algorithm should consider the loops’ length. An intramolecular quadruplex 
must have three loops to link the tetrads together and they play a large role in determining 
both the stability and folding pattern of the quadruplex. In summary loops with lengths from 1 
to 7 bases were found to form quadruplexes  with stability decreasing as length increased 
(Huppert JL et al. 2005).
Most  of these computational  analysis  pointed  out  three key repetitive  functional  domains 
characterized by high PQS: the telomeres, the ribosomal DNA (rDNA) and, in mammals, the 
immunoglobulin heavy-chain switch regions. High PQS also characterizes repetitive G-rich 
microsatellites,  including  some  of  the  most  unstable.  In  the  human  genome,  more  than 
300000 distinct sites have potential to form quadruplex (Huppert JL et al. 2007). 
Several kinds of evidence support the functional importance of these sites. 
First,  specific  sequence motifs  are  evident  at  sites with high PQS, particularly within the 
loops  separating  G-runs.  Second,  among  single-copy  genes,  PQS  correlates  with  gene 
function as defined by gene ontology terms. Notably PQS is low in tumor-suppressor genes, 
which maintain genomic stability and are commonly haploinsufficient; but it is high in proto-
oncogenes,  which  promote  cell  proliferation.  Quadruplex  formation  can  correlate  with 
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genomic instability and the low PQS of tumor-suppressor genes may results in selection that 
protects genes in this class from instability. The high PQS of proto-oncogene is more difficult  
to explain, but there is an intriguing possibility that it may reflect shared regulation (Maizels 
N 2006). 
Quadruplex can led to genomic instability and this has been taken into account by De and co-
workers (2011) resulting in the finding that genomic regions, rich in quadruplexes, are on 
average hypermethylated in normal tissue; hypomethylation in those region is substantially 
associated with DNA breakpoint hotspots across a wide range of cancer types. Quadruplex 
structures and aberrant hypomethylation have a key role in generating genomic alteration and 
cancer (De A et al. 2011). At the same time one should keep in mind that whereas methylated 
CpGs restrict transcription, unmethylated CpGs in the vicinity of a gene allow that gene to be 
expressed  (Saxonov  S  et  al.  2006).  Genome  wide  analyses  have  shown  that  PQS  does 
correlate with GC-content but not with the number of CpG island. Both exons and introns 
contribute to the difference in PQS between tumor suppressor genes and proto-oncogenes. In 
fact tumor suppressor genes have much lower PQS than would be predicted by their genomic 
environment as compared to the RefSeq genes, whereas proto-oncogenes have higher PQS 
than would be predicted. The most straightforward interpretation of these results is that genes 
with specific functions have undergone selection based on quadruplex potential (Eddy J et al. 
2006). Notably almost 50% of PQS contain CpG dinucleotides and, for a majority of those 
cases,  the  guanine  participates  in  quadruplex  formations.  PQS  show  depletion  of  CpG 
methylation and nucleosome occupancy,  and DNA methylation pattern have a role in the 
stability  of  other  non-canonical  DNA structures  such  as  Z-DNA and  H-DNA.  Extensive 
hypomethylation and high quadruplex frequency rarely co-occur in normal tissues (De A et 
al. 2011). 
In  normal  tissues,  the  genome  is  usually  hypermethylated  and  does  not  show  genomic 
instability, whereas genome-wide hypomethylation is a hallmark of many cancer types.
2.1.2.  Quadruplex binding proteins
It  is  known  that  quadruplexes  are  recognized  by  different  proteins  and  this  raises  the 
possibility  that  such  proteins  could  serve  not  only  to  recognize  the  structure  but  also  to 
promote or inhibit formation of quadruplex in vivo. At telomere level there are lots of proteins 
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able  to  bind  the  two  different  conformations  of  telomeres:  the  double  strand  and  the 
quadruplex conformation (Shafer RH et al. 2001). For what concern the quadruplex structure 
proteins,  human replication protein A and hnRNP A1 are able  to  bind to the quadruplex 
telomeric end and induce telomerase activation by unfolding the quadruplex (Salas TR et al. 
2006, Zhang QS et al. 2006). Other than these proteins, components of telomeric complexes 
such as POT1 (Protection Of Telomere) and TriPeptidyl Peptidase 1 (TPP1) proteins are able 
to recognize the single and four-stranded DNA of telomeres and allow their elongation by 
telomerase (Zaug AJ et al. 2005). This happens not only in human chromosome ends but even 
in  Oxitricha nova and  Stylonychia  mytilis,  two  kind  of  ciliated  protozoa,  in  which 
homologous proteins of POT1 and TPP1, namely Telomere End-Binding Protein α (TEBP α) 
subunit and TEBP β subunit, are involved in telomere binding triggering telomerase activity 
(Wang F et  al.  2007).  Another  protein  of the telomere  binding-proteins  complex such as 
hnRNP D is able  to bind, in this  case with the Binding Domain 2 (BD2) subunit,  to the 
quadruplex structure of the telomere and to unwind it (Enokizono Y et al. 2005). 
Quadruplex binding proteins are found not only in telomeres but also in other part of the 
chromosomes. hnRNP A1 and its derivative Up1 for example are able to recognize and affect 
KRAS promoter sequence as we saw in the initial part of my PhD (Paramasivam M et al.  
2009). Up1, the catalytic fragment of hnRNP A1 was identified in 1975 by Herrick et al.  
(Herrick G et al. 1976) in calf thymus as a protein that greatly destabilizes regions of DNA 
double helix by virtue of its selective affinity for single-stranded over double-stranded DNA. 
In particular proteins involved in triplet amplification diseases, such as the Bloom’s syndrome 
and the Werner’s syndrome, which are members of the RecQ family of helicases (BLM and 
WRN), are able to unwind DNA in the 3’ to 5’ direction in the presence of ATP and Mg2+ 
(Shafer  RH et  al.  2001).  The functions  of  these enzymes  involves  unwinding quadruplex 
structures that may form as undesired intermediates in recombination or replication, which 
would explain the observed aberrant phenotype when they are defective (Shafer RH et al. 
2001).  Even in the fragile  X syndrome expanded triplet  some quadruplex-binding protein 
have been found to recognize this  structure.  Human quadruplex Telomeric  DNA Binding 
Protein  42  (qTBP42)  and  unimolecular  quadruplex  Telomeric  DNA  Binding  Protein  25 
(uqTBP25) share close homology with the hnRNP-derived mammalian single-stranded DNA-
binding proteins Up1 (Weisman-Shomer P et al. 2000) and mouse CarG-box binding factor A 
(hnRNP AB),  both  containing  the  RNP1 domain.  They  destabilize  quadruplex  structures 
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within  the  triplet  amplification  and  this  decreases  the  probability  of  expansion  of  the 
d(CGG)n sequence (Weisman–Shomer P et al. 2002). 
The high degree of conservation of telomeric quadruplex-forming sequence and the existence 
of proteins that interact  with quadruplexes and have telomere roles, such as RecQ family 
helicases,  Ras  proximate  1  (Rap1)  and  Pif1  of  Saccharomyces  cerevisiae and  the 
corresponding mammalian TRF2, suggest that this feature may be an important component of 
telomere function (Smith JS et al. 2011). Pif1 protein has been studied in yeast and is able to 
recognize and bind quadruplex before and after replication because its regulatory function can 
be exerted in two steps: in the first moment it binds the quadruplex to unwind it, allowing cell  
to go throughout the cell cycle and then unwinds the quadruplex motifs again after replication 
as a sort of failsafe mechanism that makes sure that genome is free of quadruplex structures 
prior to chromosome condensation (Paeschke K et al. 2011).
Other than this, MyoD was one of the earliest proteins known to recognize quadruplexes. This 
protein is involved in the regulation of skeletal muscle development playing an important role 
in cellular differentiation (Shafer RH et al. 2001). In particular the intact basic part of MyoD 
is essential for the binding of E-box motif d(CANNTG) in promoters or enhancers of muscle-
specific genes (Shklover J et al. 2007). 
Another well known protein able to recognize and modulate the quadruplex structure folding 
or unfolding is Pur1 known also as Myc Associated Zinc-finger (MAZ) protein. This protein 
can bind to several promoters, such as the GAGA box in the rat insulin promoter, as well as  
the insulin-linked polymorphic region (ILPR) involved in genetic susceptibility to insulin-
dependent diabetes mellitus (Shafer RH et al. 2001). MAZ is also able to recognize the c-myb 
promoter repressing its activity (Palumbo SL et al. 2008). Last but not least MAZ is able to 
bind  HRAS promoter quadruplex-forming sequences and unwind them, as described in the 
final part of this thesis (Membrino et al. 2011).
Not only MyoD or MAZ where found to bind to different promoter sequences but other gene 
promoters  require  the  intervention  of  quadruplex-binding  proteins  to  activate  or  repress 
transcription of the downstream gene.  For example in our laboratory  KRAS promoter was 
found to  present  a  quadruplex-forming  sequence  recognized  by nuclear  proteins,  such as 
PARP-1, Ku 80, Ku 70 and hnRNP A1 (Cogoi S et al. 2008). Even Sp1 is able to bind to  
KRAS promoter region (Hoffman EK et al. 1990). NM23-H2 a metastases suppressor factor 
interacting  with  the  c-MYC promoter  is  able  to  induce  c-MYC expression  unfolding  the 
quadruplex structure created by the NHEIII motif (Thakur RK et al. 2009). In the promoter of 
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c-MYC other proteins such as hnRNP K and Sp1 are also able to regulate its transcription 
activity  (Tomonaga  T  et  al.  1996).  Nucleophosmin,  a  nucleo-cytoplasmic  shuttling 
phosphoprotein known to favour quadruplex formation, is able to recognize and bind c-MYC 
promoter quadruplex-forming region (Federici T et al. 1996). The nucleocapsid protein of the 
HIV-1 virus is also able to unfold quadruplex in the presence of Zn2+ (Kankia BI et al. 2005).
This amount of proteins that recognize quadruplexes support the evidence of an evolutionary 
pressure  working to  maintain  quadruplex-forming  sequences  in  the  genome as  regulatory 
elements of different cellular mechanisms.
2.1.3. Quadruplex DNA in promoter regions
Different studies have been done on quadruplex-forming sequences and their localization into 
the human genome. What came out from these analysis is that quadruplex structures can be 
possibly  involved  into  regulatory  mechanisms  concerning  replication,  transcription  and 
transduction. Most frequently quadruplex studies focused on promoter regions of different 
genes involved in cancers because they are hyperexpressed in different kinds of cancers. For 
example the first well studied promoter region has been the control element situated upstream 
of  the  P1  promoter  for  the  c-MYC oncogene  (Shafer  RH  et  al.  2001).  Even  a 
polyguanine/polycytosine tract found in the proximal promoter of the Vascular Endothelial 
Growth Factor (VEGF) has been shown to form specific secondary structures, characterized 
as quadruplexes and I-motifs; the latter located in the complementary C-rich sequence (Guo K 
et al. 2008). The proximal 5’-flanking region of the human Platelet-Derived Growth Factor A 
(PDGF-A) promoter contains one Nuclease Hypersensitive Element (NHE) able to fold into 
quadruplex  structures  and  modulate  transcription  (Qin  Y  et  al.  2007).  c-KIT oncogene 
presents a possible parallel-type quadruplex arrangement in its promoter region (Rankin S et 
al. 2005). Finally the RAS genes present quadruplexes in their promoter region such as KRAS 
(Cogoi  S  et  al.  2004)  and  HRAS (present  thesis,  Membrino  A  et  al.  2011),  regulating 
transcription,  and in the 5’UTR of the  NRAS proto-oncogene which modulates translation 
(Kumari S et al. 2007).
Being  involved  in  so  many  functional  processes  quadruplex  structures  could  be  seen  as 
therapeutic  targets.  Cylene  Pharmaceutical  (San  Diego,  USA)  has  developed  CX-3543 
(Quarfloxin),  which can disrupt the interaction between nucleolin and a quadruplex DNA 
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structure  in  the  ribosomal  DNA template,  and  this  compound  has  now entered  phase  II 
clinical trials (Ou T et al. 2008). Stabilizing the quadruplex structure involved in transcription 
regulation can allow the blockage of transcription. For example Isoalloxazines can interact 
with the  c-KIT oncogene (Ou T et al. 2008), 2,6-diamido anthraquinones (e.g. BSU-1051) 
(Hurley LH 2001), cationic porphyrins (e.g. TMPyP4) (Han H et al. 2000), perylenes (PIPER) 
(Neidle S et al. 2001), metal-free phthalocyanines (Azleer J et al. 2009, Membrino A et al. 
2010),  oxazole-based  peptide  macrocycles  (Jantos  K et  al.  2006),  TriArylPyridine  ligand 
family (TAPs) which disrupts the quadruplex and enhance transcription of the  c-KIT gene 
(Waller ZAE et al. 2009). All these different molecules can interact with quadruplexes by 
placing themselves on the top or the bottom of the structure, between tetrads or in the grooves 
(Neidle  S et  al.  2009).  To investigate  on new molecule  properties  of  binding quadruplex 
DNA, a simple and high throughput technique is competition dialysis in which a nucleic acid 
structure is dialyzed against different kind of molecules (Ragazzon P et al. 2007). This has 
allowed to understand the binding affinity of some molecules used for quadruplex binding.
Given  that  quadruplex-forming  sequences  regulate  gene  transcription,  and  sometimes 
translation, are recognized by nuclear proteins and can be bound by artificial molecules, a 
strategy to modulate quadruplex-related genes is to use synthetic oligonucleotides resembling 
the sequence of interest. This would subtract proteins necessary to exploits the quadruplex 
function  in vivo. Some G-rich libraries strongly inhibited cancer cell growth while sparing 
non-malignant cells (Choi EW et al.  2010) and many quadruplex-forming sequences have 
been  created  by  SELEX  technique  and  tested  on  cancer  cell  lines  after  an  initial 
characterization  of  their  features  by CD (Paramasivan S et  al.  2007),  S1 hypersensitivity 
-given that Homopurin-homopyrimidine stretches adopting unusual DNA conformations are 
more sensible (Pestov DG et al. 1991)-, NMR and structural crystallography. Quadruplex-
forming  sequences,  when  introduced  into  cells,  can  be  used  as  therapeutic  agents.  They 
competed for the binding between transcriptional factors and the host quadruplex structure of 
interest  (Bates  PJ  et  al.  1999).  For  example  G-rich  oligonucleotides  which  form 
intramolecular quadruplexes have been used to inhibit Stat3 protein avoiding its binding to 
DNA (Jing N et al. 2004). The most recent synthetic oligonucleotide that reached phase II 
clinical trial is AS1411 a quadruplex-forming oligonucleotide able to target nucleolin (Teng 
Y et al. 2007).
The advantages of using quadruplex oligonucleotides as therapeutic agents is that they are 
non-immunogenic,  heat  stable  and they have increased resistance to serum nucleases  and 
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enhanced cellular uptake compared to unstructured sequences (Bates PJ et al. 2009). Different 
techniques have been studied to enhance their delivery into cells such as modification of the 
oligonucleotide bases with lipophilic conjugation (Spiller DG et al. 1998) or with modified 
oligonucleotides as shown in this thesis (Membrino et al. 2011). 
Already, quadruplexes are both targets for drug design and potential therapeutic drugs in their 
own  right.  Guanine  quartets  are  suspected  in  some  deoxyribozimes  because  of  the  K+ 
dependence  of  the  enzymatic  activity.  The discovery of  fluorescent  dyes  that  specifically 
target quadruplexes shows promise for locating and tracking their formation within the cell. 
There will be, in the future, more applications utilizing structures containing quadruplexes, 
particularly  biologically  active  aptamers  selected  by  systematic  evolution  of  ligands  by 
exponential enrichment (SELEX) techniques and structural studies will play a role in these 
applications. Not all future applications will be biomedical. Quadruplexes show promise as 
components for nanowires, ion channels and building blocks for directing the assembly of 
nanoscale components into sophisticated structures (Keniry MA 2001).
2.2. RAS
2.2.1. Bladder cancer
The specialized lining of the urinary tract, the urothelium, which extends from the renal pelvis 
to the urethra, is a source of the 5th most common cancer, responsible for approximately 3% 
of all cancer-related deaths in the United States. In the Western world, cigarette smoking is 
the most  important  risk factor,  contributing to approximately 50% of all  bladder cancers, 
followed by petrochemical and other industrial exposures. Bladder stone, chronic indwelling 
Foley catheters,  schistosomiasis,  and chemical  irritations  are well-documented risk factors 
(Dinney CP et al. 2004). The peak prevalence of the disease is among patients 60-70 years old 
(Vangeli D et al. 1996).
The human  RAS genes represent an important prototypical family of cellular transforming 
genes originally  identified  in  the T24 human urothelial  cancer  cell  line  (Reddy EP et  al. 
2004). Transformed cells  exhibit  changes in nuclear  morphology and chromatin structure. 
Cancer is often diagnosed by an abnormal nuclear morphology. Also fibroblasts transformed 
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with oncogenes including  HRAS have an abnormal nuclear morphology: the nuclei show a 
more  rigid  and  spherical  shape  (Dunn KL et  al.  2005).  Two mechanisms  for  RAS gene 
transformation have been discovered. The most frequent is mutation of codons 12, 13, 59 or 
61, which affect  the enzymatic  activity of the protein.  In the second mechanism, internal 
splicing  within  the  last  intron  mediates  RAS gene  expression.  Mutations  of  the  coding 
sequence of the  HRAS gene,  especially at  codon 12, are  relatively frequent,  appearing in 
approximately 30-40% of urothelial malignancies (Dinney CP et al. 2004).  RAS activation, 
via point mutation, overexpression or intensified signalling from Fibroblast Growth Factor 
Receptor 3 (FGFR3), occurs in 70-90% of bladder tumors in humans. 
Cell growth is normally under the tight control of positive regulators (proto-oncogenes and 
growth factors) and negative regulators (senescence- and apoptosis-inducing molecules and 
tumor suppressors) of cell  cycle progression. It is the intricate balance between these two 
opposing forces that  ensures the necessary tissue renewal  while  maintaining  homeostasis. 
Such a balance is not static, but rather is quite dynamic, particularly when cells are called 
upon to respond to various pathogenic insults. When an oncogene is activated by mutation, 
affected cells can turn up senescence and tumor suppressor genes to counter the oncogenic 
effects, thereby regaining cell-cycle control and putting a brake on cell proliferation. Failure 
to do so could lead to uncontrolled proliferation and tumorigenesis (Mo L et al. 2007).
2.2.2. Pancreatic cancer
Each year are diagnosed 28000 pancreatic tumours and almost all the affected people dye 
because of this tumour, making it one of the first causes of death in the world. 85% of the 
patients  do  not  show  any  chance  of  intervention  to  solve  the  problem  because  of  the 
formation of metastasis and the dramatic invasiveness of the tumor. The remaining part of the 
patients can barely hope in life expectation that does not exceed 5 years.
More than 90% of pancreatic cancers are related to the exocrine part of the organ. The origin 
of the neoplasias  is  due to point mutation that  can be found into the genealogic  trees  of 
families  with an high degree of pancreatic  cancer.  There are no doubts about the genetic 
origin  of  pancreatic  cancers  and  their  prognosis  involves  the  accumulation  of  molecular 
abnormalities inside the ductal pancreatic cells. 
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In the tumorigenesis  of pancreatic cancer are involved different suppressor genes that are 
altered so to be unable to control the cell cycle and so develop neoplasia. The most important  
of these repressor genes is p16 located in the 9p21 chromosome that is altered by means of 
mutations,  deletions  and  hypermethylations  of  DNA.  Another  gene  involved  into  the 
tumorigenic  development  of  pancreatic  cells  is  Deleted  in  Pancreatic  adenoCarcinoma  4 
(DPC4) located in chromosome 18q, inactivated only in 50% of cancers due to mutations and 
allelic  deletions.  Even p53, one of the most  common genes inactivated in  tumor cells,  is 
inactivated in 50-70% of pancreatic cancers. The tumorigenic transformation of pancreatic 
cells can be due to genomic abnormalities of BRCA2 gene usually associated to breast and 
ovarian cancers.
In pancreatic cancer the most mutated gene is  KRAS located in chromosome 12p12.1 being 
one of the first events in pancreatic tumor progression.     
2.2.3. RAS family
RAS genes  were  originally  identified  in  the  mid-1960s  as  the  transforming  elements  of 
Harvey and Kirsten strains of rat sarcoma viruses. Investigation of the biological properties of 
their protein products did not start until the early 1980s, when mutated alleles of cellular RAS 
genes were identified as dominant oncogenes in various types of tumors. Mutations within the 
RAS genes  have  been  reported  in  diverse  tumors  including  myeloid  leukemia,  colon, 
pancreatic, thyroid, and renal cell carcinomas (Burmer GC et al. 1989).
RAS genes are expressed at low level in most tissues (Jordano J et al. 1986). The RAS genes 
are  expressed in  a  tissue-specific  fashion:  HRAS is  highly expressed  in  skin and skeletal 
muscles, KRAS in colon and thymus and NRAS in male germinal tissue (Lory DR et al. 1993). 
HRAS,  KRAS and  NRAS have  been  found  in  a  significant  percentage  of  human  tumors 
activated by somatic mutation of their corresponding normal proto-oncogene (Jordano J et al. 
1986). The RAS genes have all similar structures and sequences with five exons, the first of 
which  is  not  encoding,  and  conserved  splicing  sites.  The  introns,  instead,  have  different 
lengths and sequences (Lory DR et al. 1993).
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2.2.4.  RAS proteins
The three mammalian  RAS genes encode four highly related GTPases of 188 (K-RASB) or 
189 (HRAS, NRAS, and K-RASA) amino acids in length. The A and B isoform of  KRAS 
diverge solely in their COOH-terminal 25 amino acids (Campbell SL et al. 1998) generated 
by an alternative  splicing  of  the  fourth exon of  this  gene,  and the abundance  of  KRASB 
transcripts is higher in comparison to that of KRASA transcripts (Bar-Sagi D 2001). The RAS 
family comprises other homologous proteins such as RRAS, TC21, RAP and RAL (Rebollo 
A et al. 1999). RAS proteins are ubiquitously expressed and located at the inner side of the 
plasma membrane (Bos JL 1998).
RAS  proteins  are  membrane-bound  guanosine  triphosphate  (GTP)/guanosine  diphosphate 
(GDP)-binding (G) proteins that act to relay signals from the lipid-rich cellular membrane to 
the nucleus (Lee JT et al. 2002). RAS superfamily GTPases function as GDP/GTP-regulated 
molecular switches (Wennerberg K et al. 2005). RAS proteins exist in two conformations, a 
GTP-bound active state and a GDP-bound inactive state: the ratio of GTP to GDP bound to 
cellular  RAS proteins  is  controlled  by Guanine  nucleotide  Exchange Factors  (GEFs)  and 
GTPase-Activating  Proteins  (GAPs),  the  enzymatic  activity  of  which  responds  to 
extracellular stimuli such as growth factors (Downward J 1998). All of the critical domains 
for GTPase function are present within the N-terminal 165 amino acids of RAS proteins. RAS 
proteins are made of three contiguous region. The first region encompasses the N-terminal 86 
amino acids, which are 100% identical among the different RAS proteins. Within this regions 
lies the RAS effector binding domain (amino acids 32-40) which is the critical interaction site 
with all known downstream targets of RAS. The next 80 amino acids define the second region 
where mammalian RAS proteins diverge only slightly from each other, exhibiting an 85% 
homology  between  any  protein  pair.  The  remaining  C-terminal  sequence,  known  as  the 
hypervariable region, starts at amino acid 165 and shows no sequence similarity among RAS 
proteins  except  for  a  conserved  CAAX  motif  (C,  cysteine;  A,  aliphatic  amino  acid;  X, 
methionine or serine) at the very C-terminal end, which is present in all RAS proteins and 
directs post-translational processing (Bar-Sagi D 2001).
RAS proteins are post-translationally modified by prenylation,  a process that involves the 
addition  of  a  15-carbon  farnesyl  isoprenoid  moiety  to  the  conserved  CAAX  motif  by  a 
farnesyl protein transferase (FPT). After prenylation, the C-terminal tripeptide is removed by 
proteolysis and the newly exposed C-terminal is methylated. In addition to post-translational 
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modifications, RAS proteins require binding of GTP to develop functional activity (Rebollo 
A et al. 1999). 
RAS effectors preferentially bind to the GTP-bound state of RAS. Two regions of RAS differ  
in conformation between their GDP- and GTP-bound states. They are referred to as Switch I 
and Switch II. The Switch I region is composed of residues 30-38, which constitute part of the 
L2 loop and part of the β2 β strand. Within Switch I, residues 32-38 are conserved among all 
members  of the RAS subfamily,  so specificity  determinants  must  lie  outside this  core of 
conserved residues.  The Switch II  region comprises  residues 60-76 and is  highly mobile, 
existing in multiple conformation (Marshall CJ 1996). The GTP-bound conformation exhibits 
increased affinity for downstream effectors (Mitin N et al. 2005).
RAS, discovered in two urothelial cancer cell lines (T24 and EJ), was the first named human 
oncogene in the early 1980. Although  HRAS (as opposed to  KRAS and  NRAS) remains the 
main target of mutational activation in bladder tumors, the mutation frequency in different 
patients cohorts ranges from 0% to 84%, with no satisfactory explanation for such a wide 
variations. More than half of the human bladder tumors overexpress RAS mRNA and protein. 
In addition, several Receptor Tyrosine Kinases (RTKs) are believed to be constitutively active 
in human bladder tumors (Mo L et al.  2007). Not only do RTKs activate  RAS-dependent 
pathways  that  drive  proliferation,  but  they  activate  PI3K-dependent  pathways  which  also 
contribute  to  the  oncogenic  mechanism.  PI3K can  initiate  changes  in  gene  transcription, 
cytoskeletal changes through β-catenin, changes in cell mobility through the tumor suppressor 
Adenomatous  Polyposis  Coli  (APC)  and  phosphorylation  of  BAD,  a  protein  involved  in 
apoptotic and anti-apoptotic signalling (Porter AC et al. 1998).
Low-level  expression  of  the  activated  HRAS  could  induce  urothelial  hyperproliferation, 
leading to simple urothelial hyperplasia. In a study conducted by Mo et al. after a long (>10 
months) incubation with the activated form of HRAS, about 60% of transgenic mice develop 
low-grade,  non-invasive papillary bladder  tumors  (Mo L et  al.  2007).  Such a  long tumor 
latency and incomplete penetrance suggest that a rate-limiting step is present during persistent 
simple  urothelial  hyperplasia  and  that  a  cooperating  event,  such  as  the  loss  of  a  tumor 
suppressor gene must take place in order to efficiently transform the urothelium. Inactivating 
senescence-inducing molecules such as p16Ink4a and p19Arf, acting through Rb and p53, 
have been shown to be a prerequisite for cells to escape senescence and become transformed 
(Mo L et al. 2007).
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Emerging evidence suggests that tumorigenicity of activated  RAS in a specific tissue also 
depends on the spectrum and the extent of the signalling pathways that  RAS exploits. The 
signal  of  activated  RAS  is  propagated  mainly  through  three  structurally  distinct,  but 
functionally overlapping, signalling cascades: a. the Raf/Mek/Erk (MAPK) cascade, which 
promotes cell proliferation, b. the PI3K/AKT cascade, which mediates cell survival, and c. the 
Ral guanine nucleotide exchange factor (RalGEF)/Ral family GTPase, which was recently 
shown to be important for transformation and tumorigenesis (Mo L et al. 2007) (Figure 8).
Figure 8
Perentesis JP, Bathia S, et al. RAS oncogene mutations and outcome of therapy for childhood acute lymphoblastic Leukemia 2004, 18, 
685-692
Quantitative differences in the expression level of activated  HRAS plays  a crucial  role in 
determining the time course of urothelial tumor development and high-level expression of an 
activated  HRAS is  sufficient  to  induce  urothelial  tumorigenesis  along  the  low-grade, 
noninvasive phenotypic pathways (Mo L et al. 2007). 
However, the measured expression levels in a tissue does not necessarily reflect the levels in 
cultured cells where the RAS mutation occurs (Bos JL 1989).   
2.2.5.  Strategies to inhibit RAS
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Three main approaches to inhibit RAS-mediated signalling have been explored: a. prevention 
of  membrane  localization  of  RAS,  b.  inhibition  of  RAS protein  expression  via  antisense 
nucleotides or RNAs and c. inhibition of kinases downstream of RAS (Lee JT et al. 2002). 
In order for RAS to become active, it must undergo post-translational modifications that add 
farnesyl or geranylgeranyl isoprenoid moieties to its carboxy-terminus. These modifications 
are generated by three different enzymes, namely farnesyltransferase, geranyltransferase type 
I and type II. By blocking the enzymatic action of these enzymes, RAS is unable to localize to 
the cellular membrane where it mediates proliferative signaling. 
The antisense approach uses oligonucleotides, which are complementary to mRNA transcripts 
of the  RAS oncogene.  These oligonuleotides hybridize to the complementary mRNAs and 
inhibit their subsequent translation into proteins. 
The  kinase  inhibition  approach  would  involve  Raf-1  by  the  use  of  RNA  aptamers  or 
synthesizing proteins that are able to antagonize the binding between RAS and Raf or others 
such as  Protein  Kinase C,  Mitogen-activated  protein Kinase-1/2 (MEK-1/2),  Extracellular 
signal-Regulated Kinase (ERK1 and 2).   
2.2.6. HRAS promoter
As 80% of bladder tumors harbour HRAS mutations (Dinney CP et al. 2004) and more than 
half  of  bladder  tumors  overexpress  HRAS (Vageli  D  et  al.  1996),  both  mutation  and 
overexpression are important  factors  in  the tumorigenesis  of bladder  cancer  (Mo L et  al. 
2007). HRAS mutations are less common, but they have a high prevalence in skin papillomas 
and urinary bladder tumors (Schubbert S et al. 2007). Indeed, it has been recently shown that 
low-level  expression of constitutively active  HRAS induces simple  urothelial  hyperplasia, 
while  the doubling of activated  HRAS oncogene triggers  rapidly growing and penetrating 
tumors  throughout  the  urinary  tract.  HRAS promoter  contains  numerous  copies  of  the 
GGGCGG element. This G-box has been shown to interact with the Sp1 transcription factor  
(Ishii  S et al.  1985, Ishii S et  al.  1986). Upstream of the TSS there are runs of guanines 
spanning over three Sp1 sites, which are potential sites for quadruplex formation. We thus 
hypothesized that the G-rich elements might play a role in transcription regulation. 
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For what concerns HRAS in its –1 intron there is a repetitive element that may contribute to 
mature HRAS mRNA but its precise role in regulation of transcription is unknown (Lownder 
NF  et  al.  1990).  Within  this  region  HRAS contains  a  short  GC-rich  promoter  which  is 
sufficient to express the transformation activity of the HRAS oncogene. This element located 
between position –1418 and –1368 upstream of the first coding ATG is the minimum element 
necessary to activate HRAS transcription (Honkawa H et al. 1987). 
The promoter of the human HRAS gene lacks typical TATA, CAAT boxes and contains an 
extremely high G+C content (80%) and multiple copies of the heptanucleotide GGGCGGG 
repeat (G-box). Because of this G-richness, in our laboratory we focused on two sequences 
namely hras-1 (435-462, accession number J00277) and hras-2 (506-530, accession number 
J00277) the first of which locates upstream the TSS and the latter spanning over it. These two 
sequences  are  potentially  capable  to  fold  into  intramolecular  quadruplex  structures 
(Membrino  A  et  al.  2011). According  to  a  recent  study,  quadruplex-forming  sequences 
covering Sp1 binding elements are present in many genes (Todd AK et al. 2008). 
We have obtained a  first  hint  that  the  HRAS promoter  is  structurally  polymorphic  while 
sequencing  expression  vectors  bearing  the  wild-type  or  the  mutated  version  of  it.  When 
primer-extension reactions were performed with primers complementary to the G-rich strand, 
Taq  polymerase  unexpectedly  arrested  at  the  G-rich  elements.  But  with  primers 
complementary  to  the  C-rich  strand  no  impediment  was  detected. An  insight  into  the 
quadruplexes formed by the HRAS G-elements was obtained by DMS-footprinting, Circular 
Dichroism  (CD)  and  Fluorescence  Resonance  Energy  Transfer  (FRET)  experiments 
(Membrino A et al. 2011). 
Focusing on the role of these two sequences we built up a construct harbouring the luciferase 
gene driven by HRAS promoter sequence and two related mutants each mutated in one of the 
two quadruplex-forming sequences. We had strong evidences that in the presence of wild type 
sequences,  transcription  is  strongly  inhibited.  This  inhibition  was  even  stronger  in  the 
presence  of  quadruplex  binding  molecules  such  as  TmPyP4  (Sun  D  et  al.  2008) and 
phtalocyanines DIGP and DIGP-Zn (Membrino A et al. 2010).
This was the first hint that made us think at HRAS promoter structures as negative regulators 
of transcription. 
To explore whether hras-1 and/or  hras-2 are involved in  transcription regulation,  we first 
asked if these G-rich elements are recognized by nuclear proteins. Using an on-line software 
called MATInspector available on genomatix website, we checked whether hras-1 and hras-2 
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sequences were recognized by any nuclear factor. And we obtained as a result two highly 
probable binders of these sequences such as Myc Associated Zinc-finger (MAZ) protein and 
Specificity protein (Sp) 1. Both of them are transcriptional factors. MAZ is a 48,6 KDa zinc-
finger protein whose consensus sequence is GGGAGGG, contains six C2H2-type zinc fingers 
at  the  C-terminus,  a  proline  rich  region  and  three  alanine  repeats  and  it  is  ubiquitously 
expressed, albeit at different levels in different human tissues (Song J et al. 2001). Sp1 is a 
80,7 KDa protein belonging to the Sp/KLF transcription factor family (Krüppel-like factor) 
divided into two different transcriptional parts: the Sp group that prefers GC rich sequences 
and the KLF group that prefers GT rich sequences. Sp1 consensus sequence is GGGCGGG 
but can bind, even if less strongly, to GGGA/TGGG sequences (Wiestra I et al. 2008). Sp1 is 
ubiquitously expressed, and contains three C2H2-type zinc fingers, two serine and threonine-
rich  domains  and  two  glutamine-rich  domains;  the  C-terminus  of  Sp1  is  involved  in 
synergistic activation and interactions with other transcriptional factors (Song J et al. 2001). 
To confirm the predicted binding we checked by EMSA and ChIP assays if those proteins 
bound hras-1 and hras-2 sequences, by which degree and to which structural conformation 
given that previous studies have shown that MAZ and Sp1 often bind to the same sequence 
regulating transcription in a cooperative way (Leroy C et al 2004, Song J et al. 2001). 
Based on the results  obtained we suggest  a  model  explaining  what  we inferred from our 
experimental data concerning HRAS transcription. 
HRAS promoter  quadruplex-forming  sequences  usually  act  as  repressors  of  transcription 
(Figure 9).
Figure 9
This  effect  can  be  enhanced  by  adding  quadruplex  stabilizers  such  as  porphyrins  or 
guanidinio phthalocyanines (Figure 10).
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Figure 10
At the same time HRAS promoter quadruplexes are required to recruit essential transcription 
factors. Once these factors, such as MAZ and Sp1, bound the quadruplexes they can resolve 
the blocks and enhance transcription (Figure 11).
Figure 11
2.2.7. Affecting HRAS expression
Considering our model as a possible explanation of what happens in the cell we focused our 
attention  on  affecting  HRAS transcription.  Possible  strategies  are:  a.  stabilizing  HRAS 
quadruplex structures or b. inhibiting nuclear quadruplex-binding factors. 
The former option is achieved by the usage of porphyrins (TmPyP4) and phthalocyanines 
(DIGP and DIGP-Zn).  They are able  to  bind and block  HRAS promoter  sequence into  a 
quadruplex structure and this lead to inhibition of HRAS transcriptional levels (Figure 10). 
The latter option can be achieved in two different ways: a. down-regulating MAZ and Sp1 
genes by mean of siRNAs or b. competing the direct binding of MAZ and Sp1 to  HRAS 
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quadruplexes  using  modified  oligonucleotides  (decoys)  mimicking  hras-1  and  hras-2 
sequences. For this purpose we designed G4-decoys oligonucleotides, mimicking the  HRAS 
quadruplexes,  with  (R)-1-O-[4-(1-Pyrenylethynyl)phenyl-methyl]  glycerol  and  LNA 
modifications to increase their stability and nuclease resistance (Figure 12). Decoy 3, 4 and 5 





























Exploiting the first way we saw that inhibiting MAZ and Sp1 led to HRAS down-regulation 
while using decoys MAZ and Sp1 proteins were sequestered from  HRAS promoter. In this 
way transcription was abolished (Figure 13).
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Figure 13
The designed decoys caused a potent antiproliferative effect in T24 bladder cancer cells, as 
they  repressed  transcription  by  sequestering  MAZ  and  Sp1.  Caspase  and  FACS  assays 
showed that the G4-decoys promoted an antiproliferative effect mediated by apoptosis.  
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3. Aim of the work
The aim of my PhD was to study the impact of DNA quadruplex structures formed by critical  
G-elements located in the promoters of the RAS genes, in particular KRAS and HRAS. 
The three-year work has mainly focused on the role played by quadruplex DNA in controlling 
transcription.  In  our  laboratory,  we found that  HRAS and  KRAS promoters  show similar 
features: a. they lack TATA and CAAT boxes; b. they are rich in guanines; c. they contain 
runs  of  guanines  in  virtue  of  which  the  G-element  can  fold  into  an  unusual  quadruplex 
structure. Previous studies from our laboratory showed that the KRAS promoter is recognized 
by the nuclear factors hnRNP A1, Ku 70, Ku 80 and PARP-1. 
In the first  part  of my PhD I have investigated the nature of the interaction between the 
proteins hnRNP A1 and UP1 (a proteolitic fragment of hnRNP A1) and quadruplex DNA. We 
setup a Fluorescence Resonance Energy Transfer (FRET)-melting technique to demonstrate 
that hnRNP A1/UP1 unfold the bound quadruplex. 
In the second part of my PhD work I focused on HRAS: a proto-oncogene that is mutated in a 
big part of bladder cancers and that is for this reason a primary target of anticancer agents. 
We have studied for the first time how transcription is controlled in this gene and we have 
discovered  that  transcription  is  activated  by  the  transcription  factors  MAZ and  Sp1  and 
inhibited by quadruplex structures formed by promoter sequences overlapping the binding 
sites for MAZ and Sp1.   
According to  the  transcription  model  proposed for  HRAS,  we have  developed two novel 
strategies to down-regulate it in bladder cancer cells: a. use of decoy oligonucleotides that, 
mimicking  the  natural  quadruplexes  formed  by  the  HRAS promoter  sequences,  bind  and 
subtract transcription factors necessary to activate transcription; b. use of quadruplex ligands 
such guanidinio phthalocyanines that, stabilizing quadruplex DNA, lock the HRAS promoter 
in the folded and not active form. 
With the results of this work four articles have been published in high impact-factor journals. 
Details of the work are given in the “Results” session of this thesis.  
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4. Results
4.1.   Protein hnRNP A1 and its  derivative Up1 unfold quadruplex DNA in the human 
KRAS promoter: implications for transcription.
Previous studies done in our laboratory involving human KRAS proto-oncogene showed that it 
contains a structurally polymorphic nuclease hypersensitive element (NHE) whose purine strand 
forms a parallel quadruplex structure (called 32R). From pull-down experiments published in 
previous work done by Xodo and co-workers (2008) our laboratory reported that quadruplex 
32R can be recognized by three nuclear proteins: PARP-1, Ku70 and hnRNP A1. We focused on 
hnRNP A1 (A1) and its derivative Up1 producing them as recombinant proteins and we started 
working on their ability to interact with  KRAS promoter quadruplex. We performed some CD 
analysis of the 32R sequence folded as a quadruplex in the presence of the two proteins. The 
results  obtained demonstrate  that  these proteins  strongly reduce the intensity  of the 260 nm 
ellipticity. This means that these two proteins are able to unfold the KRAS quadruplex. FRET-
melting  experiments  revealed  that  A1/Up1 completely abrogates  the  quadruplex  structure  of 
KRAS promoter.  This  was thought  to  be  the  initial  step  towards  the  annealing  between the 
polypurine strand and its complementary sequence into the cell to inhibit transcription. When 
quadruplex  32R  is  stabilized  by  TMPyP4,  hnRNP  A1/Up1  brings  about  only  a  partial 
destabilization of the quadruplex structure. Based on this we suggested a possible regulatory 
model for  KRAS transcription. In this model we stated that  KRAS  promoter is in equilibrium 
between the double strand and the quadruplex conformation. When the quadruplex is folded, 
transcription is allowed due to protein recognition of this unusual structure of DNA. Starting 
from this hypothesis  we suggested two strategies  to  down-regulate  KRAS transcription.  This 
should be achieved: a. using quadruplex ligand molecules that stabilize KRAS promoter into the 
quadruplex conformation or b. using decoy molecules that should sequester quadruplex binding 
proteins.
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ABSTRACT
The  promoter  of  the  human  KRAS  proto-oncogene 
contains  a  structurally  polymorphic  nuclease  hyper-
sensitive element (NHE) whose purine strand forms a 
parallel  G-quadruplex  structure  (called  32R).  In  a 
previous  work  we  reported  that  quadruplex  32R  is 
recognized  by  three  nuclear  proteins:  PARP-1,  Ku70 
and  hnRNP A1.  In  this  study  we  describe  the  inter-
action of recombinant hnRNP A1 (A1) and its deriva-
tive  Up1  with  the  KRAS  G-quadruplex.  Mobility-shift 
experiments show that A1/Up1 binds specifically,  and 
also with a high affinity, to quadruplex 32R, while CD 
demonstrates  that  the  proteins  strongly  reduce  the 
intensity  of  the  260  nm-ellipticity—the  hallmark  for 
parallel  G4-DNA—and  unfold  the  G-quadruplex. 
Fluorescence  resonance  energy  transfer  melting 
experiments reveal that A1/Up1 completely abrogates 
the  cooperative  quadruplex-to-ssDNA  transition  that 
characterizes the KRAS quadruplex and facilitates the 
association  between  quadruplex  32R  and  its 
complementary  polypyrimi-dine  strand.  When 
quadruplex  32R  is  stabilized  by  TMPyP4,  A1/Up1 
brings about only a partial  desta-bilization of  the G4-
DNA structure. The possible role played by hnRNP A1 
in the mechanism of KRAS transcription is discussed.
INTRODUCTION
The  mammalian  KRAS  gene  encodes  for  a  guanine 
nucleotide-binding protein of 21 kDa that activates several 
cellular  pathways  controlling  important  events  such  as 
proliferation,  dierentiation  and  signalling  (1).  The  Ras 
proteins behave as a molecular switch cycling between
inactive GDP-bound and active GTP-bound states. The state 
of  nucleotide  occupancy  is  regulated  by  specific  pro-teins 
named  guanine  nucleotides  exchange  factors  (GEFs)  and 
GTPases activating proteins (GAPs) (1,2).  The RAS genes 
are frequently mutated in solid and haematological neoplasias 
with single point mutations at exons 12, 13 and 61 (3,4). The 
most common mutated RAS gene in solid tumours is KRAS, 
with  a 90% incidence in pancreatic adenocarcinomas (5,6). 
As the mutated Kras protein has a defective GTPase activity, 
it is not inactivated by GAPs
(7).  It  remains  locked  into  the  GTP-bound  active  state 
which  continuously  transmits  to  the  nucleus  mitotic  sig-
nals that contribute to the neoplastic phenotypes in cancer 
cells  (8–10).  As  pancreatic  adenocarcinomas  are 
refractory to conventional treatments, the discovery of new 
drugs capable to sensitize tumour cells to chemotherapy is 
being pursued in many laboratories. In our laboratory, we 
focused on KRAS and in order to design anti-KRAS drugs 
we  investigated  how  the  transcription  of  this  proto-
oncogene is controlled. Previous studies have shown that 
a nuclease hypersensitive element (NHE), located in the 
KRAS  promoter  upstream  of  the  transcription  start 
between –327 and –296,  is  responsible for  most  of  the 
transcription  activity  (11).  Earlier  we  reported  that  the 
purine  strand of  NHE is  structurally  polymorphic,  as  its 
tract of sequence recognized by nuclear proteins is able to 
fold into stable G-quadruplex structures (12,13). Using the 
purine strand of NHE (called 32R) in quadruplex confor-
mation  as  a  bait,  we  pulled  down  from  a  pancreatic 
nuclear  extract  three  proteins  with  anity  for  the  KRAS 
quadruplex.  By SDS–PAGE and mass spectrometry,  we 
identified these proteins as poly[ADP-ribose] polymerase 1 
(PARP-1),  ATP-dependent  DNA  helicase  2,  subunit  1 
(Ku70) and heterogeneous ribonucleoprotein A1 (hnRNP 
A1)  (13).  Protein  hnRNP  A1  (from  now  on  A1)  is  a 
member  of  the  heterogeneous  ribonucleoprotein  family, 
which is highly abundant in the nucleus of actively
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growing  mammalian  cells  (14,15).  All  members  of  the 
hnRNP family are characterized by two highly conserved 
RNA recognition motifs (RRMs) at the N-terminus and by a 
glycine-rich domain at the C-terminus (16,17). Although a 
recent structure of a co-crystal of Up1 (a pro-teolitic portion 
of  A1  retaining  binding  activity)  bound  to  the  telomeric 
repeat (TTAGGG)2 suggests that both RRMs interact with 
DNA (18), it has been reported that only one motif (RRM1) 
is sucient for strong and specific binding to single-stranded 
telomeric  DNA  (19)  and  that  its  sub-element  RNP11 
mediates  destabilization  of  quadru-plex  (CGG)n (20). 
Proteins hnRNP play various roles in mRNA metabolism 
(14,15)  and  in  the  biogenesis  of  telo-meres  (21).  As 
protein A1 (and its derivative Up1) was reported to have a 
telomere-lengthening eect in erytro-leukemia cells (21,22), 
it  is  suspected  to  function  as  an  auxiliary  factor  of  the 
telomerase holoenzyme (23). Considering that the 30 G-
rich  repeats  of  the  telomeres  are  folded  in  stable  G-
quadruplex structures,  it  has been hypothesized that  A1 
stimulates  telomere  elongation  by  disrupting  high-order 
structures formed by the telomere repeats.  Indeed,  Up1 
was  reported  to  destabilize  the  bimo-lecular  quadruplex 
formed by human telomere repeats d(TTAGGGTTAGGG), 
d(TTAGGG)4 and  the  intramo-lecular  quadruplex  of 
d(GGCAG)5 (23–25).
Since we discovered that A1 is associated to the KRAS 
promoter,  in  this  study  we  have  investigated  the  inter-
action  between  recombinant  A1/Up1  and  the  KRAS  G-
quadruplex.  Electrophoretic  mobility  shift  assay  (EMSA) 
showed that A1/Up1 binds to the KRAS quad-ruplex with 
high  anity  and  specificity,  while  CD  and  fluorescence 
resonance energy transfer (FRET) experi-ments revealed 
that A1/Up1 destabilizes this non B-DNA structure of the 
KRAS  promoter.  The  results  of  our  study  support  a 
transcription mechanism in which A1 should function as a 
G-quadruplex destabilizing protein, as it seems to occur in 
the G-rich  30 overhang strand of  the  telomeres (23).  In 
conclusion, this study sheds some light on the mechanism 
of KRAS transcription regulation and may be useful for the 
rationale design of anticancer drugs specific for oncogenic 
KRAS.
MATERIALS AND METHODS
DNA and proteins hnRNP A1/Up1
The oligonucleotides used in this study (Table 1) were 
obtained  from  MWG  (Germany)  and  Microsynth 
(Switzerland). They have been purified by 20% PAGE 
(acrylamide:  bisacrylamide,  19:1)  in  TBE,  under 
denatur-ing  conditions  (7  M  urea,  558C).  The  bands 
were excised from the gel and eluted in water. The DNA 
solutions  were  filtered  (Ultrafree-DA,  Millipore)  and 
precipitated.  DNA concentration was determined from 
the  absorbance  at  260  nm  of  the  oligonucleotides 
diluted in  milli  Q water,  using as extinction coecients 
7500, 8500, 15 000 and 12 500 M_1 cm_1 for C, T, A 
and G, respectively. Dual-labelled F-32R-T (50 end with 
FAM, 30 end with TAMRA) were HPLC-purified.
Recombinant proteins Up1 and A1 tagged to GST were 
expressed in Escherichia coli BL21 using plasmids
pGEX-Up1 and pGEX-hnRNP A1. After transformation, the 
bacteria were grown for 2 h at 378C with 50 mg/ml 
ampicillin to an A600 of 0.5–2.0 prior to induction with IPTG 
(100 mM final concentration). Cells were allowed to grow 
for 7 h before harvesting. The cells were centrifuged at 
5000 r.p.m., 48C. After centrifugation the supernatant was 
removed carefully and the cells washed twice with PBS. 
The pellet was re-suspended in a solution of PBS with 
PMSF 100 mM and DTT 1 M. The bacteria were lysed by 
sonication, added with Triton X-100 (1% final 
concentration) and incubated for 30 min on a shaker at 
room temperature. The lysate was then centrifuged for 10 
min at 48C at 10 000 r.p.m. Glutathione Sepharose 4B 
(GE Healthcare) (50% slurry in PBS) was added to the 
supernatant and incubated for 30 min at 48C on a shaker. 
The mix was centrifuged for 5 min at 500 g and the pellet 
was washed 5 times in PBS and eluted with elution buer 
containing 20 mM NaCl, 20 mM reduced glu-tathione, 200 
mM Tris–HCl, pH 9.5 for A1 elution and pH 7.5 for Up1 
elution. Alternatively, to remove the GST tag, the mix was 
centrifuged for 5 min at 500g, washed with PreScission 
Cleavage buer (GE Healthcare) and centrifuged 5 min at 
500g. The pellet was incubated for 4 h at 48C with 
PreScission protease to cleave the GST tag from the 
purified proteins. After PreScission cleavage, the A1 or 
Up1 moieties were detached from GST which remained 
bound to the Gluthatione Sephadex beads. The reaction 
mixtures were centrifuged for 5 min at 500g, 48C, and the 
untagged proteins collected from the supernatant. Finally, 
the purification of tagged and untagged Up1 and A1 
proteins were checked by SDS–PAGE.
CD and fluorescence experiments
CD spectra have been obtained with a JASCO J-600 
spec-tropolarimeter equipped with a thermostatted cell 
holder.  CD  experiments  were  carried  out  with 
oligonucleotides (3  mM) in  50 mM Tris–HCl,  pH 7.4, 
100 mM KCl. Spectra were recorded in 0.5 cm quartz 
cuvette. A ther-mometer inserted in the cuvette holder 
allowed  a  precise  measurement  of  the  sample 
temperature.  The  spectra  were  calculated  with  J-700 
Standard Analysis software (Japan Spectroscopic Co., 
Ltd)  and  are  reported  as  ellipticity  (mdeg)  versus 
wavelength  (nm).  Each spectrum was recorded three 
times, smoothed and subtracted to the baseline.
Fluorescence measurements were carried out with a 
Microplate  Spectrofluorometer  System  (Molecular 
Devices) using a 96-well black plate, in which each well
contained  50 ml  of 200 nM dual-labelled F-32R-T in
50 mM  Tris–HCl, pH  7.4 and  KCl  as specified in
the figure captions. Before adding the protein, the samples 
were incubated for 24 h at room temperature in the speci-
fied buer. The protein (Up1, A1 or BSA) was added 30 min 
before fluorescence analysis. The emission spectra were 
obtained by setting the excitation wavelength at 475 nm, 
the cut-o at 515 nm and recording the emission from 500 
to  650  nm.  Upon  addition  of  KCl,  F-32R-T  assumes  a 
folded  quadruplex  conformation  and  FRET  is  expected 
between  the  50 and  30 fluorophores.  The  emission 
intensity  of  the  donor  (FAM)  decreases  while  the 
intensity of the acceptor increases, correspondingly, as 
K+ is added to the sample solution. The energy transfer 
from the donor to the acceptor and vice versa can be 
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empirically represented by the parameter P:
where ID and IA are the intensities of the donor and accep-
tor (26,27).  Fluorescence melting experiments were  per-
formed on a real-time PCR machine (iQ5, BioRad), using a 
96-well plate filled with 50 ml solutions of dual-labelled F-
32R-T. The protocol used for the melting experiments is 
the  following:  (i)  equilibration  step  of  5  min  at  low 
temperature  (158C);  (ii)  stepwise  increase  of  the 
temperature of 18C per min for 76 cycles to reach 958C. 
All samples in the wells were melted in 76 min.
Kinetic experiments were carried out using the iQ5 real-
time machine.  Oligonucleotide F-32R-T (200 nM) in 100 
mM KCl, i.e. in the quadruplex conformation, was mixed 
with  the complementary 32Y strand and the increase at 
525 nm of the fluorescence was measured as a function of  
time.  The experiment  was  also  performed adding  to  F-
32R-T a mixture containing 32Y (8-fold)
and  Up1  (400 nM). The increase of  fluorescence
F = F _ F0, where F0 and F is the fluorescence at
525 nm (FAM) at t = 0 and at any time t, was best-fitted 
to a single or double-exponential curve. The half-life of 
the reaction is given by t1/2 = 0.693/k.
EMSA
Oligonucleotides  32R,  HRAS-1,  HRAS-2,  CMYC,  CKIT, 
VEGF, 32Y, Gmut1 and Gmut2 were end-labelled with [g-
33P]ATP  and  T4  polynucleotide  kinase.  Duplex  dsNHE 
was  prepared annealing  (10  min  at  958C,  over-night  at 
room  temperature)  a  mixture  containing  equimo-lar 
amounts of radiolabelled 32R and complementary 32Y in 
50 mM Tris–HCl, pH 7.4, 100 mM NaCl. Before EMSA, the 
quadruplex-forming oligonucleotides were
allowed to form their structure in 50 mM Tris–HCl,
pH  7.4, 100 mM KCl, 378C  (overnight  incubation).
Radiolabelled oligonucleotides (35 nM) were treated for 30 
min at room temperature with dierent amounts of A1/Up1, 
(r ([protein]/[oligonucleotide]) ratios are specified in Figure 
3) in 20 mM Tris–HCl, pH 8, 30 mM KCl, 1.5 mM MgCl2, 1 
mM DTT, 8% glycerol, 1% Phosphatase Inhibitor Coktail I 
(Sigma, Milan, Italy), 5 mM NaF, 1 mM Na3VO4, 2.5 ng/ml 
poly [dI-dC]. After incubation, the reaction mixtures were 
loaded in 8% TBE (1_) polyacrylamide gel, thermostatted 
at 168C. After running the gel was dried and exposed to 
autoradiography (G E Healthcare, Milan) for 24–36 h at –
808C.
Polymerase-stop assay
A  linear  DNA  fragment  of  87  nt,  containing  the  G-rich 
element of NHE, was used as a template for Taq polymer-
ase primer-extension reactions. This DNA sequence was 
purified by PAGE. The template (100 nM) was mixed with 
the labelled primer (50 nM) in 100 mM KCl, Taq buer
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1_ and overnight incubated at 508C. The primer extension 
reactions were carried out for 1h, by adding 10 mM DTT, 
100  mM dATP,  dGTP,  dTTP,  dCTP and 3.75 U of  Taq 
polymerase (Euro Taq, Euroclone,  Milan).  The reactions 
were  stopped  by  adding  an  equal  volume of  stop  buer 
(95%  formamide,  10  mM  EDTA,  10  mM  NaOH,  0.1% 
xylene  cyanol,  0.1%  bromophenol  blue).  The  products 
were separated on a 15% polyacrylamide sequencing gel 
prepared  in  TBE,  8  M  urea.  The  gel  was  dried  and 
exposed  to  autoradiography.  Standard  dideoxy 
sequencing reac-tions were performed to detect the points 
in which DNA polymerase I was arrested.
RESULTS
We previously demonstrated that the G-rich strand of NHE 
can form G-quadruplex  structures  (13,28).  By means of 
CD and DMS-footprinting experiments we found that the 
G-tract  called  32R  forms  a  parallel  G-quadruplex 
characterized by three G-tetrads (Tm of 708C in 100 mM 
KCl)  (Figure  1).  Pull-down  assays  with  a  pancreatic 
nuclear extract combined to mass spectrome-try showed 
that quadruplex 32R binds to three proteins: PARP-1 (116 
kDa), Ku70 (72 kDa) and A1 (34 kDa) (13). Since A1 is 
involved in the biogenesis of the telomeres as a G4-DNA 
destabilizing  protein  (23)  and  is  able  to  disrupt  the 
secondary  structures  of  the  hypervariable  minisatellite 
sequence  d(GGCAG)5 (24),  we  asked  whether  A1/Up1 
can  have  a  similar  functional  role  in  the  human  KRAS 
promoter. To address this question, recombinant A1 and 
its derivative Up1 were expressed in Escherichia coli as 
proteins fused to  GST and purified  by anity  chromatog-
raphy with glutathione sepharose 4B. The GST moiety was 
removed  with  a  pre-scission  protease  and recombi-nant 
tagged and untagged proteins were obtained with a high 
purity level (Figure 2). Up1 is a proteolitic fragment (195 
aa) of A1 (319 aa) that retains the two RNA-recogni-tion 
motifs  (RRMs)  responsible  for  binding  to  nucleic  acids 
(18,22).
The interaction between A1/Up1 and a variety of DNA 
substrates, some of which were structured in G4-DNA and 
some not, was analysed by EMSA.  33P-labelled 32R (35 
nM) was first incubated for 24 h in 100 mM KCl to allow 
quadruplex  formation,  then  incubated  for  30  min  with 
increasing amounts of Up1 or A1: r ([protein]/ [32R]) = 0, 
0.5, 1, 2, 5, 10, 20, 50, 100. As preliminary experiments 
showed that GST-tagged and untagged pro-teins behave 
in the same way,  we  performed EMSA with  the  tagged 
proteins.  Figure  3a  and  b  shows  that  quadru-plex  32R 
forms  with  A1/Up1  a  DNA–protein  complex  that,  being 
detected even at r = 0.5, should have a 1 : 1 stoichiometry.  
In addition, for r > 20, another slow-migrating DNA–protein 
complex  appears  in  the  gel,  most  likely  due  to  a  1:2 
complex. When r was increased to 200 and the samples 
run  in  a  longer  gel,  32R  migrated  essentially  as  1:2 
complex (Figure  3c).  The formation  of  two  DNA–protein 
complexes  by  A1/Up1  is  in  keeping  with  the  results  of 
Zhang et al. (23) and the crystal struc-ture of d(TTAGGG)2 
bound to Up1 (18). Since a tract of 12 nt functions as a 
minimum binding unit, 32R has
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Figure  1.  Sequence of  the  nuclease  hypersensitive  element  (NHE)  in  the  human  KRAS promoter.  The G-rich sequence 32R forms a  G-
quadruplex whose putative structure, consistent with CD and dimethyl sulfate footprinting, is G4-DNA1, which is characterized either by a flipped-
out thymidine connecting G7 to G9 or a GGGT triad (13). The expected G4-DNA2 structure is not supported by dimethyl sulfate footprinting. The 
nucleotides of 32R (Table 1) are numbered from the 50-end.























































Figure 2. Schematic representations of proteins hnRNP A1 and Up1. The two RNA-recognition motifs (RRMs), that mediate ssDNA binding,  
contain each two conserved RNP2 and RNP1 submotifs. Up1 encompasses the amino-terminal two-third of  the hnRNPA1 sequence. SDS–
PAGE of GST-tagged and untagged hnRNP A1 and Up1, after gluthatione sepharose 4B purification. Lane 1, protein markers; lane 2, total  
extract (hnRNP A1); lane 3, supernatant; lane 4, purified GST-tagged hnRNP A1; lane 5, purified untagged hnRNP A1; lane 6, total extract (Up1);  
lane 7, supernatant; lane 8, purified GST-tagged Up1; lane 9, purified untagged Up1.
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 32R  oligos
r ([A1]/[32R])
Figure 3. (a, b) EMSA of 35 nM 33P-labelled quadruplex 32R after 30 min incubation with increasing amounts of Up1 or A1 at the specified r  
values, in 20 mM Tris–HCl, pH 8, 30 mM KCl, 1.5 mM MgCl2, 1 mM DTT, 8% glycerol, 1% Phosphatase Inhibitor Coktail I (Sigma), 5 nM NaF, 1 
mM Na3VO4, 2.5 ng/ml poly dI-dC, for 258C. The analyses were carried out in 8% polyacrylamide gel (29:1) in TBE (1_) at 168C. Before the 
EMSA, 32R was incubated overnight in 100 mM KCl to get it in the G-quadruplex conformation; (c) EMSA as in (a, b) but with r values up to 200; 
(d, e) EMSA of A1/Up1 mixed to various DNA substrates [G-quadruplexes 32R, HRAS-1, HRAS-2, CMYC, CKIT, VEGF, dsNHE (32R:32Y) and  
unstructured oligonucleotides Gmut1, Gmut2, 32Y]. PAGE carried out in 8% polyacrylamide gel (29:1) in TBE (1_) at 168C.
potentially two binding sites, which can in principle form 
two DNA–protein complexes by binding one or two protein 
molecules.  By  quantifying  the  intensity  of  the 
electrophoretic  bands,  we  roughly  estimated  that  the 
dissociation constant Kd of the 1:1 complex is about 50 nM 
for Up1 and 200 nM for A1. We also tested the binding 
specificity  of  A1/Up1  for  a  variety  of  well  known  G-
quadruplex structures obtained from CMYC, CKIT, VEGF 
and  HRAS  promoter  sequences  (29–32)  (for  HRAS 
quadruplexes,  see  Supplementary  Data  S1)  (Figure  3d 
and  e).  The  various  DNA  substrates  have  been  33P-
labelled and treated with an excess of protein (r = 50). It 
can be seen that A1 shows good specificity for the KRAS 
quadruplex, as it does not bind to the other quadruplex-
forming sequences, unstructured oligo-nucleotides Gmut1, 
Gmut2,  32Y  (the  complementary  polypyrimidinic  NHE 
strand) and dsNHE (32R:32Y) (Table 1). Instead, protein 
Up1, besides quadruplex 32R, shows affinity also for the 
CKIT quadruplex and unstructured oligonucleotides.
To analyse the effect of A1/Up1 on the KRAS G-
quadruplex,  we  could  not  employ  electrophoresis 
because  the  mobility  between  an  intramolecular 
quadruplex  and  its  unfolded  form  is  not  very  different. 
Therefore,  we  used  spectroscopic  techniques  such  as 
circular dichroism (CD) and FRET. Figure 4 shows that in 
100  mM  KCl,  32R  is  characterized  by  a  CD  signature 
typical  of  a parallel  G-quadruplex:  a strong and positive 
ellipticity at 260 nm and a weak and negative ellipticity at 
240  nm  (33).  When  quadruplex  32R  is  denatured  by 
increasing the temperature, the positive 260 nm band is 
dramatically reduced and its spectrum becomes similar to 
that  of  unstructured  oligonucleotides  (data  not  shown). 
Thus, the structural transition from quadruplex-to-ssDNA 
is accompanied by a strong reduction of the 260 nm ellipti-
city. A similar transition was obtained by adding to
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quadruplex 32R increasing amounts of A1/Up1 (r = 1, 2, 4, 
6). It  can be seen that the protein causes a progressive 
reduction of the 260 nm ellipticity, indicating that the G4-
DNA structure is unfolded by the protein. As a con-trol, we 
treated  quadruplex  32R  with  an  unrelated  protein,  the 
trypsinogen inhibitor, and found that the 260 nm ellip-ticity 
was  not  aected  and  remained  constant  at  all  protein 
concentrations used. The CD spectra of Up1 at increasing 
concentrations show that the protein between 240 and 320 
nm does not have any negative band, but below 240 nm it 
shows a negative band typical of the polypeptide















F: FAM; T: TAMRA.
backbone. The CD data showing G-quadruplex unfolding 
are  in  keeping  with  those  previously  obtained  with  the 
telomeric TTAGGG repeat (24,25) and the hypervariable 
minisatellite sequence d(GGCAG)5 treated with Up1 (24).
The  unfolding  of  the  human  KRAS  quadruplex  by 
A1/Up1 was also investigated by FRET, using the quad-
ruplex-forming sequences tagged at  the 50 and 30 ends 
with FAM (donor) and TAMRA (acceptor) (34). By exciting 
F-32R-T at 475 nm, the emission intensity of the donor at 
525  nm  decreases  while  the  emission  intensity  of  the 
acceptor at 580 nm increases, as the KCl concentration is 
increased from 0 to 140 mM (Supplementary Data S2). F-
32R-T  folded  in  the  G-quadruplex  conformation  (Tm = 
758C in 140 mM KCl) is characterized by a P-value of 0.52 
(see  ‘Materials  and  methods’  section).  This  P-value  is 
higher than that observed for the quadru-plex formed by 
the  human  telomeric  repeat  d(GGGTTAG 
GGTTAGGGTTAGGG) (26), because F-32R-T forms
a parallel  quadruplex where  the  two  fluorophores
are at opposite ends of the structure (13). When the
G-quadruplex is destabilized by scaling down the KCl 
concentration to zero or by adding the complementary 
32Y strand, that transforms the G-quadruplex into a B-
DNA duplex where the donor and acceptor are sepa-
˚
rated by about 115 A, the donor fluorescence significantly 
increases (for instance, from spectrum 2 to spectrum 1, 
Figure 5a) and the P-value becomes 0.75. This means that 



























Figure 4. CD of 32R (2 mM) in 50 mM Tris pH 7.4, 100 mM KCl in the presence of increasing amounts of Up1 (r = 0, 1, 4, 6) (r = [protein]/[DNA])  
(a); hnRNPA1 r = 0, 1, 4, 6, (b); trypsinogen inhibitor (TI) (r = 0, 1, 4, 6) (c). The CD of Up1 at three concentrations is reported (2, 4 and 8 mM) 
(d). Spectra have been recorded at room temperature with a path length cuvette of 0.5 cm. Ordinate reports ellipticity values in mdeg.
“Tesi di dottorato di Alexandro Membrino, discussa presso l’Università degli Studi di Udine”
“Tesi di dottorato di Alexandro Membrino, discussa presso l’Università degli Studi di Udine”
2848  Nucleic Acids Research, 2009, Vol. 37, No. 9











20 30 40 50 60 70
Temperature (C)
100











20 30 40 50 60 70
Temperature (C)
Figure 6. –dF525/dT versus T curves in 50 mM Tris pH 7.4, 100 mM
NaCl of F-32R-T in the absence or presence of A1 (a), Up1(b), BSA at
various [protein]/[DNA] ratios.
P = 0.62) of Up1 and A1 at r = 1, 2, 3, 6, 10. It can be seen 
that,  compared  to  complementary  32Y,  Up1  does  not 
promote  a  significant  increase of  the  donor  emission,  a 
behaviour that might suggest that Up1 has little eect on the 
quadruplex conformation [for instance the P-value is 0.62 
at r = 0 (spectrum 2), 0.67 at r = 10 (spec-trum 8), P = 
0.05]. If we assume that P = 0.23 reflects total opening of 
the G-quadruplex, P = 0.05 suggests that F-32R-T bound 
to  Up1  is  partially  opened  (20%).  Alternatively,  it  is 
possible  that  F-32R-T  in  the  DNA–  protein  complex  is 
completely opened but with the 50 and 30 ends brought 
close to one another so that FRET takes place. To gain 
insight  into  this  possibility  we  per-formed  melting 
experiments. We reasoned that in case the quadruplex is 
partially  unfolded,  its  Tm would  be lowered,  whereas  in 
case it is completely opened by A1/Up1, the quadruplex-
to-ssDNA transition should be abrogated. Figure 5b shows 
typical  melting curves for quadruplex F-32R-T in 50 mM 
KCl,  obtained  with  a  real-time  PCR  machine,  after  the 
DNA was incubated for 30 min with A1/Up1 (r = 1, 2, 4, 10) 
or BSA (r = 10) just before melt-ing. It can be seen that an 
excess  of  BSA  does  not  change  the  Tm of  the  G-
quadruplex,  as  one  expects  with  an  unspe-cific  protein 
which  does  not  interact  with  DNA.  In  con-trast,  when 
quadruplex F-32R-T is incubated with A1/ Up1, a strong 
change of the melting curves is observed. The cooperative 
transition relative to the denaturation of the G-quadruplex 
(Tm of 488C) is completely abrogated and replaced with a 
broad  and  non-cooperative  curve,  which  reflects  the 
disruption of the DNA–protein com-plex. The abrogation of 
the  quadruplex-to-ssDNA  transi-tion  is  clearly  observed 
with  both  F  versus  T  and  –dF/dT  versus  T  curves.  A 
similar behaviour has been reported for the UV-melting of 
the  virus  type  1  nucleocapsid  protein  bound  to  the 
quadruplex formed by d(GGGTTGGTGTG GTTGG) (35). 
In  100  mM  NaCl,  where  quadruplex  F-32R-T  shows  a 
cooperative transition with a Tm of 328C, we also observed 
the  abrogation  of  the  cooperative  transition  by  A1/Up1 
(Figure  6).  These  data  suggest  that  when  F-32R-T  is 
bound to  A1/Up1,  its  secondary struc-ture is  completely 
disrupted and F-32R-T in the DNA– protein complex is in 
the single-stranded form. The fact that the opening of the 
quadruplex by Up1 is accompa-nied by a P which is 20% 
of  that  observed  with  32Y  (0.05  against  0.23)  can  be 
rationalized on the basis of the crystal structure between 
Up1  and  the  telomeric  repeat  (T  TAGGG)2 (18).  In  the 
crystal, the two RRM elements within a Up1 molecule bind 
to  two  separate  12mer  oligo-nucleotides,  which  are 
antiparallel and separated by an˚
interstrand distance of 25–50 A. Thus, we expect that 
F-32R-T bound to A1/Up1 adopts a U-shape with the 
two  fluorophores  close  enough  to  promote  energy 
transfer (18) (Figures 5c).
It is well  known that the cationic porphyrin TMPyP4 
stabilizes quadruplex DNA by stacking externally to the 
G-tetrads and interacting with the loop nucleotides (36). 
We  therefore  tested  whether  TMPyP4  reduces  the 
quadruplex destabilizing action of A1/Up1. Quadruplex
F-32R-T (200 nM) was incubated for 12 h in 50 mM
KCl,  in the presence of 200 and 600 nM TMPyP4.
Figure 7a shows that TMPyP4 enhances the Tm of quad-
ruplex F-32R-T from 488C (curve 1) to 68 (curve 4) and 
768C (curve 5). The mixtures were treated for 30 min with 
1 mM A1 (r = 5) and then melted. While A1 at r = 5 is able 
to completely disrupt the KRAS quadruplex in 50 mM KCl 
(see  Figure  5b),  in  the  presence  of  the  porphyrin  it 
promotes  only  a  partial  destabilization  of  the  G-quadru-
plex:  the  Tm is  reduced  from  688C  to  588C  (in  the 
presence of 200 nM TMPyP4, curve 2, Figure 7a) or from 
768C to 638C (600 nM TMPyP4, curve 3, Figure 7a). So, 
the sta-bilizing eect of  the porphyrin  partially inhibits the 
capac-ity  of  the  protein  to  unfold  the  G-quadruplex.  To 
exclude the possibility that TMPyP4 directly interacts with 
and inhibits A1, we performed a control  experiment with 
TMPyP2, the positional isomer of TMPyP4 showing lit-tle 
anity  for  quadruplex  DNA  (Figure  7b).  As  expected, 
TMPyP2  neither  stabilizes  appreciably  quadruplex  32R, 
nor  impairs  the unfolding of  the quadruplex structure by 
A1.  These  experiments  provide  a  possible  molecular 
mechanism that explains how TMPyP4 is found to repress 
the activity of the KRAS promoter (12,13).
Krainer  and  co-workers  (23)  showed  that  A1/Up1 
binds to the single-stranded and structured human telo-
meric repeat (TTAGGG)n = 2, 4. They suggest that A1 is 
likely  to  function  as  an  auxiliary  factor  of  the  telo-
merase  holoenzyme  and  propose  that  the  protein 
stimulates telomerase elongation through unwinding of 
the G-quadruplex structures formed during the
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Figure 7. (a) –dF525/dT versus T melting curves of 200 nM F-32R-T in 50 mM Tris pH 7.4, 50 mM KCl (curve 1), in the presence of 200 nM (curve 4) or 600 
nM (curve 5) porphyrin TMPyP4. Curves 2 and 3 show the melting curves obtained by F-32R-T treated with 200 nM TMPyP4+A1 (r = 5) or
600 nM TMPyP4+A1 (r = 5), respectively; (b) –dF525/dT versus T melting curves of 200 nM F-32R-T in 50 mM Tris pH 7.4, 50 mM KCl (curve 1), in the 
presence of 200 nM (curve 2) or 600 nM (curve 3) porphyrin TMPyP2. Curves 4, 5 and 6 show the melting curves obtained by F-32R-T treated
with A1 (r = 5); 200 nM TMPyP2+A1 (r = 5); 600 nM TMPyP2+A1 (r = 5), respectively. Exc 475 nm, Em 525 nm; (c) Structures of TMPyP2 and 
TMPyP4.
translocation steps.  Our study suggests  that  protein A1, 
being  a  component  of  a  multiprotein  complex  formed 
within NHE (13), may have a similar function for the KRAS 
promoter:  i.e.  to  resolve  the  folded  quadruplex 
conformations.  The  destabilizing  activity  of  A1  should 
facilitate  a  quadruplex-to-duplex  transformation,  that 
seems to be necessary to activate  transcription (12,13). 
To  test  this  hypothesis,  we  investigated  whether  the 
kinetic of hybridization between quadruplex F-32R-T and 
the  complementary  32Y  strand  becomes  faster  in  the 
presence of Up1. When quadruplex F-32R-T in 100 mM 
KCl (Tm = 708C) is mixed at 258C with the 32Y strand the 
quadruplex sequence is transformed into the more stable 
duplex  (Tm =  788C) and  the  fluorescence  of  the  donor 
increase as in the duplex it is separated from the acceptor 
(Figure 8a, from A to C). This assembly process can be 
monitored  by  measuring  the  increase  of  donor  (FAM) 
fluorescence, F, as a function of time ( F = F _ F0, where 
F0 is the FAM fluorescence at 525 nm at t = 0 and F the 
fluorescence at time t).  The F versus t curve shows an 
exponential  shape  that  was  best-fitted  to  a  double-
exponential equation (37). For the slow phase a
constant kslow of 1.56 _ 10–3 _ 6 _ 10–5 s–1 was obtained 
(Figure 8b). The hybridization performed in the presence
of  Up1 occurs  with  a faster  kinetic  which was nicely 
best-fitted to a single-exponential  equation: k = 5.2  _ 
10–3 s–1. In this case the assembly occurs between F-
32R-T  bound  to  Up1  and  32Y,  the  fluorescence 
increases from B to C (Figure 8b). The half-life t1/2 for 
the hybridization of 32R to 32Y in the presence of Up1 
is 133 s, while in the absence of Up1 is 444 s, i.e. more 
than  3  times  higher.  This  demon-strates  that  Up1 is 
indeed a G4-DNA destabilizing protein  that  facilitates 
the quadruplex-to-duplex transformation within NHE.
Finally,  by a primer extension assay using a template 
containing the  KRAS G-rich  element  we  tested whether 
A1/Up1 is  able to remove the block to Taq polymerase 
caused  by  quadruplex  formation  (12,13,24).  Figure  9 
shows that when the template is incubated in 100 mM KCl 
prior to primer extension, Taq polymerase is arrested
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Figure 8. (a) FRET spectra of 200 nM F-32R-T in 50 mM KCl, in the 
presence of BSA (r = 10), Up1 (r = 10) and 6-fold complementary 32Y 
strand. (b) Increase of fluorescence F as a function of time following 
the addition to 200 nM F-32R-T of 6-fold complementary 32Y in 50 
mM Tris pH 7.4, 100 mM KCl. Exc 475 nm; Em 525 nm. The exper-
iment has been conducted in the absence and presence of Up1 (r = 
3). The solid lines are the best-fits of the experimental points with an 
exponential equation (SigmaPlot 11, Systat Software Inc).
at the 30 end of the G-rich tract, as this element folds into 
a G-quadruplex structure. Contrarily to what we expected, 
the  addition  of  increasing  amounts  of  protein  A1/Up1 
strengthened the pause of Taq polymerase. The precise 
points at which Taq polymerase was arrested were deter-
mined by Sanger sequencing reactions and are indicated 
with arrows in the template sequence. This suggests that 
A1/Up1 forms with the DNA template a complex which is 
suciently  stable  to  arrest  the  processivity  of  Taq 
polymerase.  That’s  why  A1/Up1  enhances  the  block  of 
Taq polymerase at the G-rich element.  However,  to cor-
roborate  this  hypothesis  DNA  footprinting  experiments 
should be done to demonstrate direct binding of A1/ Up1 
to the  site of  arrest.  The complex between A1/Up1 and 
32R is destabilized when the G-rich strand hybridizes to its 
complementary  sequence  to  aord  a  B-DNA  duplex  for 
which A1/Up1 has no anity (see EMSA). Finally, in keeping 
with  the  results  in  Figure  3,  the  primer-extension assay 
shows that A1/Up1 binds to the G-rich tract of NHE with a 
high selectivity, since significant arrests of polymerase at 
other points of the template are not observed.
DISCUSSION
This  work  describes  the  ability  of  A1,  and its  derivative 
Up1,  to  destabilize  the  quadruplexes  of  the  KRAS pro-
moter  and to  facilitate  their  hybridization  to the comple-
mentary  polypyrimidine  strand.  In  accord  with  pull-down 
experiments (13), EMSA confirmed that recombinant Up1 
and A1 bind to the KRAS quadruplex with a high anity and 
sequence-specificity, as the binding to other G-quadruplex 
structures  such  as  HRAS1,  HRAS2,  CMYC,  VEGF 
appeared either weak or inconsistent. Only the quadruplex 
from the CKIT sequence (Table 1) is recognised by Up1. 
The association of A1 to the KRAS promoter is restricted 
to the polypurine strand, as EMSA shows that A1 does not 
bind to the complementary poly-pyrimidine strand, nor to 
NHE  in  duplex  conformation.  Considering  that  the 
minimum length for strong binding to Up1 is a stretch of 12 
nucleotides (18), 32R, being com-posed by 32 nucleotides, 
has potentially two binding sites. In fact, EMSA shows that 
32R forms two DNA–protein complexes that are expected 
to have a stoichiometry of 1:1 and 1:2 (DNA:Up1). This is 
in accord with the results of Zhang et al. (23) showing that 
Up1  forms  with  the  telomeric  repeats  (TTAGGG)4 two 
DNA–protein complexes.
In  accord  with  previous  observations  (24,25),  A1  and 
Up1 promote a significant reduction of the 260 nm ellip-
ticity, typical of G4-DNA in the parallel conformation. This 
demonstrates  that  both  proteins  are  able  to  unfold  the 
quadruplex  structures  of  the  KRAS  promoter.  This 
conclusion is  further  supported by FRET-melting  experi-
ments showing that the quadruplex formed by F-32R-T is 
completely disrupted by A1 or Up1. When the KRAS G-
quadruplex  is  incubated  for  30  min  with  A1/Up1  before 
melting, the cooperative transition of the G-quad-ruplex is 
replaced  by  a  non-cooperative  transition.  This  suggests 
that when the KRAS sequence is bound to A1/Up1, it is 
open and in a single-stranded conformation, as shown by 
the  crystal  of  Up1  with  the  telomeric  repeat  (18).  In 
contrast, when a 10-fold excess BSA is added to the G-
quadruplex,  no  change  in  the  quadruplex  transition  is 
observed.  We  interestingly  found  that  protein  A1/Up1 
facilitates the assembly into a duplex of the two comple-
mentary NHE strands. In fact, the half-life of renaturation is 
reduced from 444 to 133 s in the presence of Up1, 100 
mM KCl. This is in accord with earlier studies report-ing 
that  A1  promotes  a  rapid  renaturation  of  nucleic-acid 
strands, probably by melting the secondary structures that 
are formed transiently during the annealing process (38). 
The finding that A1 resolves the KRAS quadruplexes has 
an important biological significance because previous stu-
dies supported the notion that the KRAS G4-DNA might 
behave as a transcription suppressor (12,13,28)
The role of A1 in vivo has been investigated in the con-
text  of  the  telomere  biogenesis  (21–23).  One  possible 
func-tion of the protein would be to disrupt  the G4-DNA 
structures  of  the  telomere  G-repeats,  allowing  proper 
elongation by the telomerase (23). The data of our study 
suggest that A1 could have a similar function in the tran-
scription of KRAS. This is in keeping with the fact that A1: 
(i) binds to the folded G4-DNA conformations of
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Figure 9. Primer extension assay showing that Taq polymerase pauses at the G-rich element of KRAS where the template forms G-quadruplex  
structures in the presence of KCl. The 87-mer DNA template (100 nM) was mixed with 33P-labelled primer (50 nM) (Table 1) and incubated for 24 
h in 140 mM KCl to allow quadruplex formation by the G-rich element. The mixtures were added with increasing amounts of Up1 (lanes 2–5) or  
A1 (lanes 6–8), r = [protein]/[DNA] as specified, and incubated for 30 min prior to primer extension. Taq polymerase is arrested at the G-rich  
element due to quadruplex formation. In the presence of Up1 or A1 the polymerase arrest is stronger. The points in which Taq polymerase is  
arrested, have been identified by standard Sanger sequencing reactions. Primer extension reaction performed at 378C for 1 h. Reaction products 
separated in a 12% Urea-TBE denaturing gel.
NHE but not to the complementary pyrimidinic strand or 
duplex NHE; (ii)  disrupts G4-DNA and (iii)  facilitates the 
assembly of  the NHE strands into  a duplex.  A possible 
model for transcription regulation of  KRAS is the follow-
ing.  NHE  should  exist  in  equilibrium  between  a  folded 
(quadruplex) and a double-stranded conformation. In the 
folded form the promoter is locked into a form that might 
inhibit transcription (12,13). To activate transcrip-tion, the 
folded form of NHE should hybridize to the complementary 
strand in order to restore the duplex. As the quadruplex-to-
duplex transformation is likely to be kinetically slow,  the 
functions of A1 would be of desta-bilizing the quadruplex 
and  allow  the  G-rich  strand  to  hybridize  to  its 
complementary within a time compatible with a response 
of  the  cell  to  molecular  stimuli.  There  are  a  number  of 
genes with C+G-rich elements in the region surrounding 
the transcription start site that seems to be characterized 
by  a  transcription  regulation  mechanism  involving  G-
quadruplex structures (12,13,39–45).
Several  proteins  from  dierent  organisms  that  interact 
with quadruplex DNA have been reported (46). They can 
be classified  by function into  five  major  groups:  (i)  pro-
teins that increase the stability of DNA quadruplexes;
(ii) proteins that destabilize quadruplex DNA in a non 
catalytic way; (iii) proteins that unwind catalytically 
quadruplex DNA in an ATP-dependent fashion; (iv) pro-
teins that promote the formation of quadruplex DNA;
(v) Nucleases that specifically cleave DNA at or adjacently 
to  a  quadruplex  domain.  Like  other  members  of  the 
hnRNP family such as hnRNP A2 (20) and CBF-A (20,47) 
that destabilise the G-quadruplex formed by the d(CGG)n 
fragile X expanded sequence, protein A1 acts on DNA in a 
non-catalytic  way,  i.e.  remaining  bound  to  the  DNA 
substrate. Another protein with a similar property is POT-1 
which binds to the telomere G-rich DNA over-hangs and 
disrupts G4-DNA structures (48,49). However, contrarily to 
A1/Up1,  POT-1  causes  a  significant  increase  of  the  P-
value of the quadruplex from the human telo-meric repeat, 
because in the DNA-protein complex the telomeric repeat 
assumes an extended conformation in which the donor–
acceptor are separated by a distance that is too long for 
FRET (26). Similarly, A1 disrupts the G4-DNA structures 
assumed by NHE and its remain-ing bound to the G-rich 
sequence  prevents  the  DNA  from  assuming  again  the 
folded conformation. We were indeed surprised to observe 
by primer extension experiments that
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at 378C, A1/Up1 did not remove the block to Taq poly-
merase and the protein even enhanced the polymerase 
arrest.  This  clearly  indicates that  after  interaction  the 
pro-tein  remains  bound  to  the  template,  and  the 
resulting  DNA–protein  complex  is  suciently  strong  to 
arrest the processivity of the polymerase.
Finally,  the proposed transcription regulation model 
suggests  two  strategies  to  downregulate  the  KRAS 
onco-gene and sensitize pancreatic cancer cells, which 
are  refractory  to  conventional  treatment,  to 
chemotherapy.  First,  use  of  G4-ligands  that  lock  the 
promoter  in  the  non-transcriptable  form by  stabilizing 
the G-quadru-plexes; second, use of decoy molecules 
specific  for  the  proteins  that  recognize  the  G4-DNA 
structure  of  NHE  (28).  Work  is  in  progress  in  our 
laboratory along this direction.
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HRAS promoter sequences forming G4-DNA structures
Supplementary S1: G-rich sequences located in the HRAS promoter upstream the transcription 
start site. Both sequences are recognized by proteins and assume a G-quadruplex conformation 
as indicated by CD spectra obtained in 50 mM Tris-HCl, pH 7.4, 100 mM KCl. Sequence Hras-1 
(left)  forms  an  antiparallel  quadruplex,  while  sequence  Hras-2  (right)  forms  a  parallel 
quadruplex. The CD spectra reported have been obtained as function of temperature in the 20-
90°C temperature range. 
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32R in buffer 
32R, 2.5 mM KCl 
32R, 10 mM KCl 
32R, 50 mM KCl 
32R, 100 mM KCl 
32R, 140 mM KCl 
32R+32Y, 50 nM KCl
Supplementary S2: Fluorescence spectra of 200 nM F-32R-T in 50 mM Tris-HCl, pH 7.4, at 
increasing concentration of KCl (from 2.5 to 140 mM). Exc= 475 nm, Em=550-660 nm. 
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4.2.  Cellular uptake and binding of guanidine-modified phthalocyanines to  KRAS/HRAS 
G-quadruplexes.
Focusing on KRAS and HRAS promoter sequences we identified their quadruplex structures and 
characterized  them.  Based  on  our  results  we  recognized  the  role  of  these  quadruplexes  in 
transcription.  This  result  was  supported  by  the  literature  in  which  quadruplexes  analyzed 
throughout the entire genome are found preferentially around the TSS of many genes. 
Due to the potential  to be cancer-specific targets, there is considerable interest in developing 
small  ligands  that  stabilize  quadruplexes.  The  most  famous  molecules  used  for  quadruplex 
stabilization  are  porphyrins.  Starting  from  this  approach  we  decided  to  test  some  other 
quadruplex ligands that have shape and charge complementarity with the stacked G-tetrads that 
constitute the quadruplex DNA. 
These new molecules are pyridinium and ammonium-containing porphyrazine derivatives which 
exhibited improved quadruplex specificity as compared to the widely studied, yet non-selective 
ligand 5,10,15,20-tetra(N-methyl-4-pyridyl) porphyrine (TMPyP4). 
Here,  we reported quadruplex binding from which DIGP showed its  ability to stabilize both 
parallel  and  anti-parallel  quadruplexes  while  its  zinc-containing  derivative  and  TMPyP4 
exhibited selectivity for parallel quadruplexes such as hras-2 sequence; cellular uptake showed 
that DIGP phthalocyanine enters the nucleoli while the DIGP-Zn derivative remains mainly in 
the cytoplasm. By means of luciferase reporter assay we analyzed  KRAS and  HRAS promoter 
modulation driven by this  new class of cationic phthalocyanines  consistent  with quadruplex-
mediated  promoter  inhibition  which provided interesting  results  that  stimulated  us to further 
explore the anticancer potential of guanidine-modified phthalocyanines (GPcs).
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4.3.  The  KRAS promoter responds to Myc-associated zinc finger and poly(ADP-ribose) 
polymerase 1 proteins, which recognize a critical quadruplex-forming GA-element.
KRAS promoter contains a G-rich nuclease hypersensitive element upstream of the TSS essential 
for transcription; by means of pulldown and chromatin immunoprecipitation assays we showed 
that the quadruplex is recognized by the Myc Associated Zinc finger (MAZ) and Poly(ADP-
ribose) Polymerase-1 (PARP-1) proteins. These proteins are involved in transcription because, 
when down-regulated by shRNA, KRAS transcription is inhibited. On the basis of FRET-melting 
and  polymerase  stop  assays  we  saw that  MAZ stabilizes  the  KRAS quadruplex.  When  this 
folding capacity is abrogated by specific point mutations, KRAS transcription is down-regulated. 
On the  other  hand guanidine-modified  phthalocyanines,  which  specifically  interact  with  and 
stabilize the KRAS quadruplex push the promoter activity up to more than double. 
These data support a transcription mechanism for murine KRAS that involves MAZ, PARP-1 and 
duplex-quadruplex conformational changes showing how KRAS promoter is able to behave as an 
enhancer  of  transcription  when  folded  into  quadruplex  structure  recruiting  nuclear  factors 
essential for transcription activation.
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4.4.  G4-DNA  formation  in  the  HRAS promoter  and  rational  design  of  decoy 
oligonucleotides for cancer therapy.
We focused on  HRAS G-rich promoter and we identified two runs of guanines, namely hras-1 
and hras-2, able to fold respectively into an anti-parallel and parallel quadruplex (qhras-1, qhras-
2). We demonstrated this by means of DMS Footprinting, CD and FRET-melting analysis. Given 
the abundance of the GGGCGGG element we checked if some transcriptional factors were able 
to recognize hras-1 and/or hras-2. From the literature and by means of MATInspector software 
MAZ and  Sp1  proteins  were  the  best  candidates  to  bind  hras-1 and  hras-2 sequences.  We 
confirmed this prediction in vitro by EMSA, using recombinant MAZ-gst and Sp1-gst proteins, 
and in vivo by ChIP experiments. Usually MAZ and Sp1 regulate transcription of several genes 
cooperatively or in opposite ways due to their similar consensus sequence. So we focused on 
HRAS transcription mediated by these proteins. First we silenced MAZ and Sp1 genes using 
specific shRNA and we saw an inhibition of  HRAS transcription. Than we built up a reporter 
system where luciferase expression is driven by HRAS promoter (pHRAS-luc). This showed how 
MAZ and Sp1 overexpression synergistically increased luciferase transcription. This effect was 
stronger when we used mutated forms of pHRAS-luc in which hras-1 and hras-2 quadruplexes 
were abrogated. All these findings suggested that  HRAS quadruplex-forming sequences act as 
repressors of transcription. We reasoned that sequestering MAZ and Sp1 by means of decoys 
resembling  hras-1 and  hras-2,  bearing (R)-1-O-[4-(1-Pyrenylethynyl)  phenyl-methyl]  glycerol 
and  LNA modifications  that  increase  stability  and  nuclease  resistance, would  interfere  with 
HRAS transcription. After transfection of the T24 urinary bladder cancer cell line we observed a 
repression of HRAS transcription and a strong antiproliferative effect. To go further into details 
of these phenomena we performed some competition assays by EMSA in which we competed 
the MAZ/Sp1 to hras-1/hras-2 binding with increasing amount of G4-decoys. The decoys with 
the stronger effect in vivo on HRAS transcription and cell survival were those most intensively 
competing the DNA–protein binding, especially those concerning hras-1 sequence. Furthermore 
after 24 h from decoy treatment we saw caspase 3 and 7 activation.
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Abstract
HRAS is a proto-oncogene involved in the tumorigenesis of urinary bladder cancer. In the HRAS promoter we identified two 
G-rich elements, hras-1 and hras-2, that fold, respectively, into an antiparallel and a parallel quadruplex (qhras-1, qhras-2).  
When we introduced in sequence hras-1 or  hras-2 two point  mutations that  block quadruplex  formation,  transcription 
increased 5-fold, but when we stabilized the G-quadruplexes by guanidinium phthalocyanines, transcription decreased to 
20% of control. By ChIP we found that sequence hras-1 is bound only by MAZ, while hras-2 is bound by MAZ and Sp1: two  
transcription factors recognizing guanine boxes. We also discovered by EMSA that recombinant MAZ-GST binds to both 
HRAS quadruplexes, while Sp1-GST only binds to qhras-1. The over-expression of MAZ and Sp1 synergistically activates 
HRAS transcription, while silencing each gene by RNAi results in a strong down-regulation of transcription. All these data  
indicate that the HRAS G-quadruplexes behave as transcription repressors. Finally, we designed decoy oligonucleotides 
mimicking the HRAS quadruplexes, bearing (R)-1-O-[4-(1-Pyrenylethynyl) phenylmethyl] glycerol and LNA modifications to 
increase their stability and nuclease resistance (G4-decoys). The G4-decoys repressed HRAS transcription and caused a  
strong antiproliferative effect, mediated by apoptosis, in T24 bladder cancer cells where HRAS is mutated.
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Introduction
The ras gene family consists of three functional proto-oncogenes 
(HRAS, NRAS and KRAS) that encode for guanine-binding proteins 
sharing a high homology (p21RAS) [1]. These proteins, located on the 
inner cell membrane through a farnesyl group [2], are active when 
they are bound to GTP, and inactive when GTP is hydrolyzed to GDP 
[3].  Ras  proteins  regulate  cellular  responses  to  many extracellular 
stimuli,  including mitogens  and  differentiation factors  [4].  The  ras 
genes  are  expressed  in  a  tissue-specific  fashion:  HRAS  is  highly 
expressed in skin and skeletal muscles, KRAS in colon and thymus 
and NRAS in male germinal tissue [1]. The ras genes have similar 
structures  and  sequences  with  five  exons,  the  first  of  which  is 
noncoding,  and conserved splicing sites.  The introns,  instead, have 
different  lengths  and  sequences  [1].  The  ras  proto-oncogenes  are 
converted to oncogenes by point mutations that decrease the capacity 
of the encoded protein to hydrolyze GTP to GDP, with the result that  
p21RAS remains  constitutively  active.  Hyperactivated  ras  proteins 
stimulate  phosphorylation  cascades  including  the  Raf/MEK/ERK 
pathway  which  leads  to  uncontrolled  cell  proliferation  [5,6]. 
Mutations  in  the  ras  genes  are  frequently  found  in  many  human 
tumors [7,8]. HRAS mutations are less common, but they have a high 
prevalence  in  skin  papillomas and  urinary  bladder  tumors  [9].  As 
80% of bladder tumors harbor HRAS mutations [10] and more than 
half  of bladder tumors overexpress HRAS [11], both mutation and 
overexpression are important factors in the tumorigenesis of bladder 
cancer [12]. Actually, it has been recently shown that low-
level expressions of constitutively active HRAS induced simple 
urothelial hyperplasia, while the doubling of the activated HRAS 
oncogene  triggered  rapidly  growing  and  penetrating  tumors 
throughout  the  urinary  tract.  Given  the  crucial  role  of  HRAS 
overexpression  and  mutations  in  the  tumorigenesis  of  bladder 
cancer,  one  attractive  therapeutic  strategy  could  be  to  inhibit 
HRAS transcription with  molecules  that  are  able  to  impair  the 
activity of the gene promoter. For this aim we asked how HRAS 
transcription  is  regulated.  We  observed  that  the  promoter  of 
HRAS contains numerous copies of the GGGCGGG element or 
its complement. This G-box has been shown to interact with the  
Sp1 transcription  factor  [13,14].  Upstream of  the  transcription 
start site (TSS) there are runs of guanines spanning over three Sp1 
sites, which are potential sites for G-quadruplex formation.  We 
thus hypothesized that the G-rich elements might play a role in 
transcription  regulation.  G4-DNA  are  unusual  structures 
stabilized by planar arrays of four guanines (G-quartet) linked one 
to the other by Hoogsteen hydrogen bonds [15]. The edges of the 
terminal G-quartets are connected by loops that can vary both in 
length  and  topology,  giving  rise  to  a  variety  of  different  
conformations  [16].  Genome-wide  analyses  have  revealed  that 
runs  of  guanines  are  abundant  in  gene  promoter  regions 
surrounding TSS [17–20]. It has been theorized therefore that G4-
DNA might be involved in transcription regulation [21–25]. Our 
study provides compelling evidence that HRAS transcription is 
regulated  by  the  interplay  between  Sp1,  MAZ  and  G4-DNA, 
which  acts  as  a  transcription  repressor.  On  the  basis  of  this  
discovery we have designed G-rich oligonucleotides specific for
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HRAS  which  have  a  strong  antiproliferative  effect  in  urinary 
cancer cells bearing a mutant HRAS. Although the cytotoxicity of 
certain G-rich oligonucleotides has been previously reported, their 
mechanism  of  action  is  not  yet  fully  understood  [26,27].  Our 
study  shows  that  the  designed  quadruplex-forming 
oligonucleotides  may  act  by  sequestering  MAZ  and  thus 
impairing HRAS transcription.  For their potent antiproliferative 
effect in T24 urinary bladder cancer cells, G4-decoys seem to be  
very promising effector drugs for urinary bladder cancer therapy.
Results
The HRAS promoter is structurally polymorphic
The promoter of the human HRAS gene lacks typical TATA 
and  CAAT  boxes,  contains  a  high  G+C  content  (80%)  and 
multiple  copies  of  GGGCGGG  (G-box),  recognized  by  the 
transcription factor Sp1 [13,14]. The three G-boxes closest to the 
RNA start  sites overlap quadruplex-forming  sequences,  namely 
hras-1 (435–462, accession number J00277) and hras-2 (506–530, 
J00277)  (Figure  1).  According  to  a  recent  study,  quadruplex-
forming sequences covering Sp1 binding elements are present in 
several genes [28]. We have obtained a first hint that the HRAS 
promoter  is  structurally  polymorphic  while  sequencing  the 
expression  vectors  specially  constructed  for  this  study.  When 
sequencing  primer-extension  reactions  were  performed  with 
primers  complementary  to  the  G-rich  strand,  Taq  polymerase 
unexpectedly arrested at the hras-2 or hras-1 G-rich elements. In  
contrast, with primers complementary to the C-rich strand we did 
not observe any impediment. This suggested that both hras-1 and 
hras-2 sequences formed unusual structures. Our hypothesis was 
confirmed  by polymerase-stop  assays.  We designed  two  linear 
wild-type templates containing hras-1 or hras-2 and one mutant 
template in which four GRT mutations were introduced into hras-
2  to  prevent  quadruplex  formation.  Primer-extension  reactions 
showed that Taq polymerase in the presence of potassium arrested
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at  the  39 end  of  hras-2  or  hras-1,  just  before  the  first  run  of 
guanines,  in  keeping  with  the  formation  of  a  G-quadruplex 
structure by each G-rich element (Figure S1).
Promoter sequences hras-1 and hras-2 form stable 
G4-DNA structures in vitro
An insight into the G-quadruplexes formed by the HRAS G-rich 
elements was obtained by DMS-footprinting, circular dichroism (CD) 
and  fluorescence  resonance  energy  transfer  (FRET)  exper-iments. 
Figure 2 shows the results obtained with sequence hras-1. The DMS-
footprints of 27-mer hras-1 in water or buffer containing 100 mM Li+ 
or Cs+ (lanes 1, 4, 5) show that all guanines react with DMS. Instead, 
in  the  presence  of  50,  100  or  140  mM KCl  (lanes  2,  3,  9),  the  
guanines  of  the  G-runs  A–D  are  progressively  protected,  while 
guanines G8 and  G14 in the intervening ‘‘TTGC’’  and  ‘‘CGCA’’ 
sequences are not. This cleavage  pattern suggests  that hras-1 folds 
into a G-quadruplex (qhras-1). In the presence of 50 nM TMPyP4,  
hras-1 gives a strong footprint either at low (1 mM) or high (100 mM) 
KCl concentration (lanes 7, 8) [29]. As expected, the mutant sequence 
h1-mut,  bearing  hras-1  with  four  GRT mutations  that  abolish  the 
folding,  does  not  give  any  footprint.  To  determine  the  strand 
orientation of qhras-1 we used CD (Figure 2c,d). The CD spectrum of 
qhras-1 in  100 mM KCl is  characterized by positive  and negative 
ellipticities at 287 and 260 nm, respectively, typical of an antiparallel 
conformation [30]. Heating the sample we obtained a melting curve 
(287  nm  ellipticity  versus  temperature)  that  was  not  perfectly 
superimposable  with  the  cooling  curve,  as  the  first  was  slightly 
biphasic while the second was monophasic. A more sensitive method 
of  analysis  was  obtained  by  FRET-melting  experiments  with 
sequence hras-1 end-labelled with FAM and TAMRA at the 5 and 39 
end, respectively. We obtained a well resolved biphasic melting curve 
with TM’s at 53 and 67uC indicating that hras-1 folds in at least two 
quadruplexes (Figure 2e). When the concentration of hras-1 was
Figure  1.  Sequence of  the  human  HRAS promoter  upstream of  TSS.  Two G-rich  elements  (hras-1 and  hras-2)  located  upstream of 
transcription start site can potentially fold into G-quadruplex structures. The quadruplex-forming G-rich elements contain the binding sites for  
the transcription factors MAZ and Sp1.
doi:10.1371/journal.pone.0024421.g001
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increased one order of magnitude from 200 nM to 2  mM, the TM’s 
did not change: a behavior typical of an intramolecular structure (not  
shown). Together, these data suggest that hras-1 adopts an antiparallel  
quadruplex which could  assume different  topologies:  the one  with 
lateral  loops  is  shown  in  Figure  2f  [16].  Although  we  know  by 
footprinting  and  CD  data  the  guanines  that  are  involved  in  the 
formation  of  antiparallel  qhras-1,  an  insight  into  structure  of  this 
quadruplex will only be obtained by NMR. Figure 3 shows the results 
obtained with sequence hras-2. The DMS-footprints of 24-mer hras-2 
shows that in 10, 50, 100 and 140 mM KCl (lanes 2–5), the G-runs 
A–D are protected from DMS, while G10, G12, G13, G21 and G22 
react with DMS. This indicates that the guanine triads forming the 
quadruplex should  be G3-G4-G5,  G7-G8-G9,  G14-G15-G16, G18-
G19-G20. The fact that G16 shows some reactivity to DMS suggests 
that  the  pentaguanine  G12-G16  stretch  can  participate  to  the 
quadruplex  either  with  G14-G15-G16  or  with  G13-G14-G15.  The 
mutant h2-mut sequence and wild type hras-2 in 100 mM Li+ or Cs+ 
did  not  give  any  footprint  (lanes  6–8).  The  footprinting  in  the 
presence of 50 nM TMPyP4 is  very strong (lanes 9,  10).  The CD 
spectrum of hras-2 shows a strong ellipticity at 260 nm indicative of a  
G-quadruplex  with  a  parallel  conformation  (Figure  3c)  [30].  This 
structure is so stable that the
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CD at 85uC still shows an intense 260 nm ellipticity. The stability 
at  various  KCl  concentrations  was  determined  with  sequence 
hras-2 labeled with  FAM and TAMRA. We performed FRET-
melting experiments  at  20,  40,  60,  100 and 140 mM KCl and 
obtained TM values of 78 to 82, 85,  .90 and  .92uC, respectively 
(Figure 3d). In this case, too, the TM’s did not change when the 
concentration was increased one order of magnitude (from 200 
nM to 2  mM) (not  shown).  Overall,  our  data demonstrate  that 
hras-2 forms  a  parallel  G-quadruplex  (qhras-2)  whose  putative 
structure  inferred  by  DMS-footprinting  and  CD  should  have 
either  1/1/4  or  1/2/3  loops  (Figure  3e).  A  definitive  structure 
assignment will only be possible on the basis of NMR data.
G4-DNA destabilizing point  mutations in hras-1 and 
hras-2 strongly upregulate HRAS transcription
As sequences hras-1 and hras-2 are located immediately upstream 
of the transcription start site and form in vitro stable G-quadruplexes, 
we asked what happens to HRAS transcription when the capacity of 
quadruplex formation by sequences hras-1 and hras-2 is abolished. To 
address  this  point  we  constructed  a  plasmid,  pHRAS-luc,  bearing 
firefly luciferase driven by the HRAS promoter. From pHRAS-luc we 
obtained by site-directed mutagenesis two mutant plasmids: pHRAS-
Figure  2.  The G-rich element  called  hras-1 forms an antiparallel  G-quadruplex  structure.  (a)  Wild-type (hras-1)  and mutated (h1-mut) 
sequences analyzed by DMS-footprinting. Full squares indicate DMS-reactive guanines, open squares indicate DMS-unreactive guanines;  
(b) DMS-footprinting of hras-1 in water (lane 1); hras-1 in 50 and 100 mM KCl (lanes 2 and 3); hras-1 in 100 mM CsCl or LiCl (lanes 4 and 
5); h1-mut in 100 mM KCl (lane 6); hras-1 in 50 mM TMPyP4, 1 mM KCl (lane 7); hras-1 in 50 mM TMPyP4, 100 mM KCl (lane 8); hras-1 in  
140 mM KCl (lane 9); h1-mut in 100 mM KCl (lane 10); (c) CD spectra at 25 and 90uC show that hras-1 folds into an antiparallel  G-
quadruplex; (d) Melting curves for quadruplex hras-1 obtained plotting the 287-nm ellipticity against T. A TM of about 63uC was obtained by 
heating and cooling curves; (e) FRET-melting curves of quadruplex hras-1 labelled with FAM and TAMRA show that it folds in two G-
quadruplexes with TM of 53 and 67uC (Ex. 475 nm, Em. 520 nm); (f) Possible conformations for hras-1, based on footprinting and CD data,  
are antiparallel quadruplexes with lateral and lateral/diagonal loops. The quadruplex with lateral loops is shown in the figure.
doi:10.1371/journal.pone.0024421.g002
PLoS ONE | www.plosone.org 3 September 2011 | Volume 6 | Issue 9 | e24421
“Tesi di dottorato di Alexandro Membrino, discussa presso l’Università degli Studi di Udine”
G4-DNA in HRAS Promoter and Decoy Oligonucleotides
Figure 3. Sequence hras-2 forms a parallel G-quadruplex structure. (a) wild-type and mutated hras-2 sequences analyzed by DMS-footprinting. Full  
squares indicate DMS-reactive guanines, open squares indicate DMS-unreactive guanines; (b) DMS-footprinting of hras-2 in water (lane 1); hras-2 in  
1, 10, 50, 100 mM KCl (lanes 2–5); hras-2 in 100 mM LiCl or CsCl (lanes 6,7); h2-mut in 100 mM KCl (lane 8); hras-2 in 50 nM TMPyP4, 1 mM KCl  
(lane 9); hras-2 in 50 nM TMPyP4, 100 mM KCl (lane 10). Guanines G10, G12, G13 and G21, G22 are cleaved while the other guanines are not  
(except G16 showing a low reactivity). Mutant h2-mut does not show any footprinting in 100 mM KCl; (c) CD spectra of quadruplex hras-2 at various  
temperatures between 25 and 90uC suggest the formation of an antiparallel G-quadruplex; (d) FRET-melting of quadruplex hras-2 at 20, 40, 60, 100  
and 140 mM KCl shows only one transition with TM of 78, 82, 85, .90, .92uC; (e) Possible G-quadruplex structure for hras-2, a parallel conformation 
with 1/1/4 or 1/2/3 loops, based on footprinting and CD data.
doi:10.1371/journal.pone.0024421.g003
mut1 and pHRAS-mut2, where two guanines in the second and third 
G-tetrads of the putative quadruplexes were replaced with thymine/ 
cytosine  or  thymines  (Figure  4a).  These  mutations  abrogated  the 
capacity  of  sequences hras-1 and hras-2 to  fold into a  quadruplex 
(Figure S2). The wild-type and mutant plasmids were co-transfected 
in  HeLa  cells  with  pRL-CMV,  a  vector  encoding  for  Renilla 
luciferase.  Forty-eight  hours  after transfection we measured  firefly 
and Renilla luciferases activity in the lysates of untreated and treated  
cells. The results reported in Figure 4b show that blocking quadruplex 
formation causes a dramatic increase of firefly luciferase expression, 
up to 5-fold compared to control. This strongly indicates that the G-
quadruplexes formed by sequences hras-1 and hras-2 are structural  
elements  of  the  HRAS  promoter  that  behave  as  repressors,  as 
observed for the CMYC gene [21].
G4-DNA  stabilizing  guanidinium  phthalocyanines 
repress HRAS transcription
Given that  quadruplex DNA behaves as a  repressor element  for 
HRAS,  we  examined  the  effect  on  transcription  of  G4-DNA 
stabilizing  ligands.  Due  to  their  specificity  for  G4-DNA,  in  our 
experiments we used as ligands modified phthalocyanines: tetrakis-
(diisopropyl-guanidine) phthalocyanine (DIGP) and its Zn-containing 
derivative Zn-DIGP (Figure 5a) [31–33]. HeLa cells were first treated 
with 1 or 5 mM DIGP or Zn-DIGP for 24 h and then co-transfected 
with a mixture of pHRAS-luc and pRL-CMV. After transfection, the 
cells were let to grow for 48 h before firefly and Renilla luciferases  
activity  were  measured  with  a  luminometer.  As  a  control  (i)  we 
treated the cells with TMPyP2, a porphyrin that does not bind to G4-
DNA [34]; (ii) we used as a reporter vector pHRAS-mut1 or pHRAS-
mut2  bearing  a  mutated  G-element  unable  to  form  a  quadruplex 
structure.  Figure  5b, c,  d shows that  DIGP and Zn-DIGP strongly  
inhibit  luciferase from wild-type  pHRAS-luc,  while  TMPyP2 does 
not. Moreover,  the phthalocyanines do not inhibit  luciferase in the 
cells treated with the mutant plasmids pHRAS-mut1 or pHRAS-mut2, 
in keeping with the fact that the G-quadruplexes cannot be formed by 
these vectors. These data provide further evidence that quadruplexes 
qhras-1 and qhras-2 act as transcription repressors.
Transcription factors Sp1 and MAZ bind to quadruplex 
forming sequences (QFS) hras-1 and hras-2
As our transcription data suggest that both sequences hras-1 and 
hras-2 are critical for transcription, we asked if they are recognized
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Figure 4. Effect of quadruplex DNA on HRAS transcription. (a) Two G4-DNA destabilizing point mutations in the hras-1 or hras-2 element 
have been introduced. Plasmid pHRAS-mut1 contains a mutated hras-1 element, while plasmid pHRAS-mut2 contains a mutated hras-2 
element; (b) Dual luciferase assay showing that the point mutations cause up to a 5-fold increase in HRAS promoter activity (see Figure 5 
legend). doi:10.1371/journal.pone.0024421.g004
by nuclear proteins. An answer to this question was obtained by 
mobility-shift  assays  with  a  HeLa  nuclear  extract.  Figure  6a 
shows that both HRAS duplexes form with a HeLa nuclear extract 
distinct DNA-protein complexes, thus pointing out the relevance 
of these sequences for  HRAS transcription.  Ishii  et  al.  showed 
that sequence hras-2, which contains two copies of GGGCGGG, 
is bound by Sp1 [13,14]. However, sequences hras-1 and hras-2 
should also interact with the myc associated zinc-finger transcrip-
tion  factor  (MAZ),  its  binding  site  being  (G/C)GG(C/A)GGG 
[35,36].  In  fact,  it  has  been reported that MAZ and Sp1 often 
regulate transcription in a cooperative way [37,38].
To prove that Sp1 and MAZ bind to sequences hras-1 and hras-2 
under  in  vivo  conditions,  we  performed  chromatin  immunoprecip-
itation  (ChIP)  experiments.  Living  HeLa  cells  were  treated  with 
formaldehyde  to  crosslink  the  DNA-protein  complexes,  chromatin 
was sheared into fragments and then immunoprecipitated with anti-
MAZ  and  anti-Sp1  antibodies  (Abs).  The  abundance  of  HRAS 
promoter sequences in the immunoprecipitates was measured by PCR 
using primers specific for sequences hras-1 and hras-2. The results 
reported in Figure 6b show that: IgG Ab did not immunoprecipitate 
DNA-protein  complexes  containing  sequence  hras-1  or  hras-2 
(negative  control);  anti-MAZ  Ab  did  immunopre-cipitate  a  DNA-
protein  complex  containing  hras-1  and  hras-2;  anti-Sp1  Ab pulled 
down a complex with hras-2. By measuring the intensity of the bands, 
we  found  that  the  HRAS  sequences  were  more  abundant  in  the 
immunoprecipitates with anti-MAZ and anti-Sp1 Abs than in the IgG 
Ab  immunoprecipitate.  We  thus  concluded  that  under  in  vivo 
conditions MAZ is associated to
sequences  hras-1  and  hras-2,  while  Sp1  is  associated  to  sequence 
hras-2. This was confirmed by EMSA with recombinant MAZ and 
Sp1 (Figure S3). As previous studies have shown that MAZ binds to 
G4-DNA from the murine KRAS [24] and c-myb [39] promoters, we 
explored  whether  it  also  binds  to  the  HRAS  quadruplexes.  We 
performed  EMSA  with  recombinant  MAZ  and  Sp1,  which  were 
expressed in E. coli as GST fusion proteins (Figure S4). Figure 6c 
shows  that  at  pH  7.4,  50  mM  KCl,  qhras-1  and  qhras-2  with  
increasing amounts of MAZ-GST form - in the presence of 100-fold 
excess nonradiolabelled poly d(I-C) - two retarded bands due to the 
formation of two DNA-protein complexes, most likely with 1:1 and 
1:2 stoichiometry. It is important to note that in 50 mM CsCl, where 
the HRAS sequences are unstructured (see DMS footprinting), both 
complexes  are  destabilized  indicating  that  the  DNA-protein 
interaction is mediated by the quadruplex structure. In a buffer at pH 
9 where MAZ probably modifies its own folding, the DNA-protein 
interaction is also inhibited. We also tested the binding of Sp1-GST to 
the HRAS quadruplexes and found that Sp1-GST interacts with the 
antiparallel  qhras-1 quadruplex,  but  in  a  weaker  way compared  to 
MAZ.
MAZ and Sp1 synergistically activate HRAS transcription
To prove that MAZ and Sp1 are involved in HRAS transcription, 
we  co-transfected  plasmid  pHRAS-luc  in  HeLa  cells  either  with 
pMAZ (encoding for MAZ) or pSp1 (encoding for Sp1) or with a 
mixture  of  both  plasmids  (Figure  7a).  When pMAZ or  pSp1  was 
cotransfected  with  the  reporter  vector,  the  level  of  luciferase 
expression increased by 50% compared to control.
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Figure 5. Effect of  quadruplex-stabilizing ligands on  HRAS transcription. (a) Structure of tetrakis-(diisopropyl-guanidine) phthalocyanine 
(DIGP) used, with its Zn-containing analogue Zn-DIGP, for luciferase experiments; (b) Dual luciferase assays showing that guanidinium 
phthalocyanines  DIGP and  Zn-DIGP,  stabilizing  hras-1  and  hras-2  quadruplexes,  repress  HRAS promoter  activity.  This  effect  is  not  
observed with the mutant plasmids pHRAS-mut1 and pHRAS-mut2 (control) (panels c and d). Relative luciferase is given by RT/RNT6100, 
where RT and RNT are (firefly luciferase)/(Renilla luciferase) in T24 cells treated with phthalocyanines and untreated cells. Differences from  
the control are supported by Student’s t test, P,0.05 (one asterisk), P,0.01 (two asterisks).
doi:10.1371/journal.pone.0024421.g005
When both pMAZ and pSp1 were cotransfected with the reporter 
vector, transcription increased nearly 3-fold over control, indicat-
ing that both proteins synergistically activated HRAS promoter. 
The  synergy  was  stronger  (7-fold  compared  to  control)  when 
pMAZ  and  pSp1  were  cotransfected  with  the  mutant  vector 
pHRAS-mut1 or pHRAS-mut2, bearing mutated hras-1 or hras-2 
sequences which are unable to form quadruplex structures. This 
suggests that transcription is activated when sequences hras-1 and 
hras-2 are in the unfolded duplex conformation. Furthermore, as a 
proof that transcription requires both MAZ and Sp1, we knocked 
down with validated shRNA each of the two transcription factors 
separately  (Figure  S5).  HeLa  cells  were  treated  with  shRNA 
specific for MAZ or Sp1 and the levels of HRAS transcripts were 
measured by real-time PCR, at 48 and 72 h following treatment. It  
can be seen that HRAS transcription was reduced to 30 and 20% 
of control, 48 h following treatment with anti MAZ and anti Sp1 
shRNA,  respectively  (Figure  7b).  Taken  together  our  data 
demonstrate that HRAS transcription is activated synergistically 
by MAZ and Sp1.
MAZ destabilizes the HRAS G-quadruplexes
Considering that MAZ is essential for HRAS transcription and 
recognizes  qhras-1 and qhras-2,  we  asked  whether  these quad-
ruplexes  are  unfolded  by  MAZ.  To  answer  this  question,  we 
performed  FRET-melting  experiments  with  recombinant  MAZ-
GST. Quadruplex qhras-1 end-labelled with FAM and TAMRA 
was  incubated  in  50  mM KCl,  for  30  min  in  the  presence  of 
increasing  amounts  of  MAZ-GST  or  control  protein  (BSA  or 
trypsinogen).  The melting curves (2dF/dT) showed that qhras-1 
alone melts with its typical biphasic profile with TM at 53 and 
67uC (Figure 8a curve 1). But when qhras-1 was incubated with  
MAZ-GST at (moles of protein)/(moles of DNA) ratio r = 2.5, 5, 
10 (curves 4, 5 and 6), the melting profile changed significantly 
as  the  TM’s  fell  to  ,46uC.  This  indicates  that  both  qhras-1 
quadruplexes  are  destabilized  by  MAZ-GST.  As  expected, 
unspecific proteins such as BSA or trypsinogen at r = 10 did not 
affect the melting of qhras-1 (curves 2,3). Due to its high stability 
in potassium (TM = 78uC in 10 mM KCl), qhras-2 was analyzed 
in 100 mM NaCl where the TM was 65uC. Incubated with MAZ-
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GST at r = 2.5, 5, 10, the quadruplex melted at 42uC, indicating that 
also  qhras-2  was  destabilized  by  MAZ-GST,  but  not  by  BSA or 
trypsinogen. We also ascertained that GST had no influence on the 
melting  of  the  HRAS  quadruplexes  (Figure  S6b).  An  additional 
control that we performed to rule out that bacterial proteins did not 
contribute  to  quadruplex  destabilization  was  to  mix  Glutathi-one 
Sepharose 4B resin with an extract obtained from non-transformed 
BL21 DE3 plysS bacteria. An SDS-PAGE analysis of the eluate with 
10 mM reduced glutathione showed that no bacterial proteins bound 
non-specifically to the resin (Figure S6a).
We were surprised about the unfolding activity of MAZ, as we 
recently reported that MAZ stabilized the murine KRAS quad-
ruplex  [24].  However,  it  should  be  borne  in  mind  that  MAZ 
having six zinc fingers can interact with DNA in a complex way,  
as  observed  with  qTBP42 and  CBF-A [40,41].  These  proteins 
disrupt  the dimeric  quadruplex formed by the FMR1 d(CGG)n 
repeat  but  they  also  stabilize  the  telomeric  quadruplex 
d(TTAGGG)n. CBF-4 and qTBP42 have four RNP domains but 
only  two  are  involved  in  G4-DNA  binding.  It  has  been 
demonstrated that different RNP combinations are responsible for 
either the stabilizing or the destabilizing activity.
G4-DNA decoy ODNs mimicking HRAS 
quadruplexes inhibit transcription and cell growth
Considering that HRAS transcription is activated by a combined 
action of MAZ and Sp1 and that qhras-1 and qhras-2 bind to MAZ 
(qhras-1 also binds to Sp1), we designed a decoy strategy against
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HRAS oncogene. We reasoned that these oligonucleotides mimicking 
quadruplexes qhras-1 or qhras-2 (G4-decoys) should sequester MAZ 
and inhibit HRAS transcription as well as cell growth (Figure 8c). To 
increase the stability of the G4-decoys we inserted in their sequence 
one  or  two  units  of  (R)-1-O-[4-(1-Pyrenylethynyl)  phenylmethyl] 
glycerol  (P)  to  cap  the  quadruplex  ends  [42].  To  increase  their 
resistance  against  endogenous  nucleases,  we  introduced  LNA 
residues at the 39 end and in one loop. We designed three G4-decoys 
mimicking  quadruplex  qhras-1  (3,  4  and  5)  and  three  mimicking 
quadruplex qhras-2 (6, 7 and 8) (Figure S7) (Table 2). The latter show 
CD  spectra  similar  to  that  of  wild  type  qhras-2,  with  a  strong 
ellipticity at 260 nm typical of a parallel  quadruplex conformation, 
while the former show a CD slightly different from that of qhras-1, 
with two positive ellipticities at 260 and 287 nm, suggesting that they 
should form a mixed parallel-antiparallel quadruplex [43] (Figure 9a). 
The antiprolif-erative activity of the designed G4-decoys was tested 
in two types of cells: HeLa and T24 urinary bladder cancer cells that  
harbour a mutant HRAS [codon 12 GGC (Gly) is changed in GTC 
(Val)], expressing a hyperactivated HRAS protein [44]. In a first set  
of  experiments  we  delivered  the  G4-decoys  (5  mM) without  any 
transfectant agent and did not observe any effect on cell proliferation.  
To see if this was due to a poor oligonucleotide uptake, we analyzed  
by confocal microscopy T24 bladder cells treated for 24 h with 5 mM 
decoy 3 covalently labelled with fluorescein (3-F). Figure 9b shows 
typical  images:  the  nuclei  stained  with  propidium  iodide  (red 
fluorescence), the intracellular
Figure 6. Proteins MAZ and Sp1 interact with sequences hras-1 and hras-2. (a) EMSA showing the formation of DNA-protein complexes 
between duplexes hras-1 and hras-2 and HeLa nuclear extract; amounts of extract used (mg) are indicated, radiolabelled DNA was about 4 
nM. Letters a, b and c indicate the DNA-protein complexes; (b) Chromatin immunoprecipitation analysis showing the interaction of MAZ and  
Sp1 with  sequences  hras-1 and hras-2.  The interaction  between MAZ and Sp1 with  the  HRAS sequences  was analyzed by a PCR  
amplification of 190 bp (hras-1) and 161 bp (hras-2) fragments. The two bands for complex MAZ:hras-1 have been obtained in the presence 
and absence of Mg2+ in the mixture (c) EMSA showing the binding of MAZ-GST and Sp1-GST to quadruplexes qhras-1 and qhras-2.
doi:10.1371/journal.pone.0024421.g006
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Figure 7. MAZ and Sp1 sinergistically activate HRAS promoter. (a) HeLa cells transfected with pHRAS-luc/pRL-CMV, pHRAS-luc/pRL-CMV/ 
pMAZ;  pHRAS-luc/pRL-CMV/pSp1;  pHRAS-luc/pRL-CMV/pMAZ/pSp1.  The  dual  luciferase  assays  were  performed  24  h  following 
transfection. Relative luminiscence is given by RT/RNT6100, where RNT is (firefly luciferase)/(Renilla luciferase) in T24 cells treated with only  
pHRAS-luc and pRL-CMV, while RT is (firefly luciferase)/(Renilla luciferase) in T24 cells treated with pHRAS-luc +pMAZ and/or pSp1+pRL-
CMV. Differences from the control  are supported by Student’s  t  test,  P,0.05 (one asterisk),  P,0.01 (two asterisks); (b) Level of  HRAS 
transcript in HeLa cells in which MAZ or Sp1 was knocked down by validated shRNAs.
doi:10.1371/journal.pone.0024421.g007
distribution of  the oligonucleotide (green  fluorescence)  and the 
overlay  of  both  emissions.  It  appears  clear  that  3-F  localizes 
basically in the cytoplasm, and this is the reason why the decoys 
are not active when they are delivered as free molecules. We then 
treated the cells with 3-F (350 nM) mixed to polyethylenimine 
(PEI).  Figure 9b shows that despite the low concentration,  3-F 
was efficiently taken up by the cells and uniformly distributed in 
the nucleus.  We therefore  decided to  perform our  proliferation 
experiments  using PEI as a transfectant  agent.  We did a dose-
response experiment by delivering the G4-decoys in two doses to 
T24 cells, one 48 h after the other. Three days after the first
delivery, we performed a resazurin proliferation assay. It can be seen  
that the three G4-decoys specific for hras-1 (3, 4 and 5) promoted a 
dramatic inhibition of cell growth with IC50 of about 700 nM (Figure 
9c). In contrast, only compound 6 specific for qhras-2 showed some 
antiproliferative effect in T24 cells. Remarkably, the oligonucleotides 
with  the  sequence  of  hras-1  (H1)  or  hras-2  (H2)  and  control 
oligonucleotide 1450 (not folding into a quadruplex)  did not show 
any  antiproliferative  effect  (H1  and  H2 are  probably  degraded  by 
nucleases).  A proliferation  assay  performed  as  a  function  of  time 
showed that the growth inhibition promoted by the G4-decoys did not 
weaken over a period of 144 h (Figure S8).
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Figure 8. MAZ destabilizes quadruplexes hras-1 and hras-2. FRET-melting experiment showing that in 50 mM KCl, MAZ-GST at r = 2.5, 5 and 10 (r =  
[MAZ]/[G4-DNA]) (curves 4, 5 and 6) destabilizes quadruplex qhras-1 in 50 mM KCl, 50 mM Zn-acetate [curve 1 (panel a)] and quadruplex qhras-2 in 
100 mM NaCl,  50  mM Zn-acetate [curve  1,  (panel  b)].  BSA and TR (trypsinogen) at  r  =  10 do not  have  any effect  on qhras-1 and qhras-2  
quadruplexes) (curves 2 and 3, panels a and b); (c) Schematic representation of HRAS transcription regulation proposed by this study. When the  
critical promoter elements hras-1 and hras-2 are folded, they behave as transcription repressors. This is suggested by the fact that quadruplex-
destabilizing point mutations in hras-1 and hras-2 result in a significant increase of transcription, while quadruplex-stabilizing phthalocyanines are  
found to repress transcription. MAZ, through its capacity to recognize the quadruplex structures, should be recruited to the promoter critical region.  
The MAZ-DNA interaction destabilizes the G-quadruplexes, the critical hras-1 and hras-2 elements assume a duplex conformation that favors the  
binding of Sp1 and other proteins of the transcription machinery. These events result in the activation of transcription.
doi:10.1371/journal.pone.0024421.g008
According  to  the  postulated  mechanism  of  action,  the  G4-
decoys 3, 4 and 5 should repress HRAS transcription by taking 
MAZ (and Sp1) away from the promoter. Actually, we found that 
the level of HRAS transcript, determined by real-time PCR 24 h 
after decoy treatment, was reduced up to 30% of control, in T24 
cells treated with the active decoys 3, 4 and 5 (specific for qhras-
1). In keeping with proliferation data, the decoys 7 and 8 that are 
not  active  (specific  for  qhras-2)  do  not  repress  HRAS 
transcription (Figure 10a). This result correlates with the finding 
that decoys 3, 4 and 5 strongly compete with the binding of MAZ 
to the hras-1 quadruplex, suggesting that these active decoys bind 
to MAZ (Figure 10b).
Finally,  an insight  into the killing mechanism caused by the 
designed G4-decoys  was obtained by measuring the activity of 
caspases 3 and 7 in untreated and decoy-treated T24 cells. Figure  
10c shows that decoys with the strongest antiproliferative activity 
(3,  4  and  5)  considerably  activate  caspases  3/7  (24  h  after  
treatment), suggesting that they promote cell death mediated by 
apoptosis.
Discussion
The data of this study show that HRAS transcription is activated by 
Sp1 and MAZ and repressed when the binding sites of these proteins 
closest to TSS assume a folded G-quadruplex structure.
This  is  a  new and compelling piece of  evidence  pointing to  a 
transcription mechanism which involves a simple on-off switch in 
a gene regulatory region where unusual G-quadruplexes behave 
as repressors. This was first proposed by Hurley and co-workers 
for the CMYC gene [21]. Following this transcription model we 
designed several decoy oligonucleotides in quadruplex conforma-
tion  eliciting  a  potent  antiproliferative  effect  in  T24  urinary 
bladder cancer cells bearing mutant HRAS.
ChIP assays showed that the G-rich elements called hras-1 and 
hras-2,  located upstream of  TSS,  are  bound by the zinc-finger 
proteins  MAZ  and  Sp1.  MAZ  interacts  with  these  promoter 
sequences in a complex way,  as it  recognizes  both duplex and 
quadruplex conformations of hras-1 and hras-2.  The binding to 
the  quadruplexes  is  catalytic  in  nature  as  qhras-1  and  qhras-2 
bound to MAZ go through a destabilization process that decreases 
the stability  of  the  DNA-protein  complexes  (see  EMSA).  This 
means that PAGE gives here only an apparent affinity between 
MAZ and the HRAS quadruplexes, for which we estimated a KD 
of  about  1.5  mM.  One  should  also  consider  that  by  using 
recombinant bacterially expressed proteins the binding data might 
be underestimated,  as recombinant  proteins do not undergo the 
post-translation  modifications  which  occur  in  eukaryotic  cells 
necessary for optimal binding. For instance, MAZ shows optimal 
binding to DNA when it is phosphorilated [45]. As a comparison, 
it has been estimated by a filter binding assay that recombinant
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Figure 9. Effect on cell growth of G4-decoys. (a) CD of 2 mM G4-decoys 3, 4, 5, 6, 7, 8 in 100 mM KCl, 50 mM Tris-HCl, pH 7.4, cuvette 0.5 cm;
(b) confocal microscopy images of T24 cells treated with decoy 3 labelled with fluorescein in the presence and absence of 
polyethylenimmine (jet-PEI). Top panel shows the nuclei stained with propidium iodide, mid panel shows the intracellular distribution of the 
decoy, bottom panel shows the overlay; (c) Dose response assays in T24 urinary bladder cancer cells treated with the G4-decoys at 
increasing concentrations (100, 200, 300, 400, 600 and 800 nM - double delivery); differences from the control are supported by Student’s t 
test, P,0.05 (one asterisk), P,0.01 (two asterisks). doi:10.1371/journal.pone.0024421.g009
nucleolin binds to parallel quadruplexes with a KD between 79 to 
367 nM and it binds to mixed parallel antiparallel quadruplexes 
with  a  KD of  0.45–2.5  mM [46].  Instead,  by surface  plasmon 
resonance assay it has been found that recombinant nucleophos-
min binds to the CMYC quadruplex with a KD of 1.9 mM [47].
MAZ was identified as a G-box binding transcription factor for 
CMYC [48]. Previous studies have shown that MAZ can either 
activate [35–37,49–51] or repress [39,52] transcription. Further-
more, in certain genes MAZ regulates transcription together with 
Sp1, as the two proteins can bind to the same guanine blocks: the 
consensus  sequence  for  MAZ  is  G(g/c)GGc/a  GGGG(c/a)(g/t) 
while  that  of  Sp1  is  (g/t)GGGCGG(g/a)(g/a)(c/t)  [35].  When 
MAZ  or  Sp1  was  separately  knocked-down  with  specific 
shRNAs,  HRAS  transcription  dropped  respectively  to  30%  or 
20% of  control.  Conversely,  when  MAZ and  Sp1  were  over-
expressed,  a  synergistic  effect  was  observed  and  HRAS 
transcription increased 3-fold compared to control.
To  explore  the  role  of  G4-DNA  on  HRAS  transcription  we 
introduced two quadruplex destabilizing GRT(C) point mutations in 
sequences hras-1 or hras-2 and found that transcription increased 5-
fold compared to control. A similar behavior was previously reported 
for CMYC and CMYB genes [21,22,39]. Our conclusion is
that  both HRAS G-quadruplexes  behave  as  a  molecular  on-off 
switch that either provides the binding sites to MAZ and Sp1 or  
subtracts  them.  This  is  also  supported  by  the  fact  that 
guanidinium phthalocyanines stabilize the HRAS G-quadruplexes 
and repress luciferase from pHRAS-luc to 20–30% of control, but 
not  from  mutant  vectors  pHRAS-mut1  and  pHRAS-mut2.  In 
addition to function as a transcription factor, MAZ is also able to 
remove the structural blocking of transcription by the quadruplex 
structures, as indicated by FRET-melting data.
In  the  light  of  all  these  findings,  we  designed  G4-decoys 
mimicking HRAS G-quadruplexes, which show a strong antipro-
liferative activity in T24 urinary bladder cancer cells harboring 
mutant HRAS. We hypothesized that the G4-decoys should take 
MAZ away from the promoter and inhibit  HRAS transcription. 
We found that in T24 bladder cells (but also in HeLa cells, not 
shown) the decoys specific for quadruplex qhras-1 (3, 4, and 5) 
displayed  a  dramatic  inhibitory  activity  on  cell  growth,  at  a 
concentration as low as 700 nM. Instead, only decoy 6 mimicking 
quadruplex  qhras-2  showed  some  activity.  In  keeping  with 
previous observations, our data suggest that quadruplex formation 
per se is not sufficient to give rise to a bioactivity, as decoys 7 
and 8 though forming a stable quadruplex, are not active.
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Figure 10. Effect of G4-decoys on  HRAS transcription. (a) Real-time PCR determination of the HRAS transcripts in T24 urinary bladder  
cancer cells treated with 800 nM G4-decoys specific for hras-1 and hras-2 for 24 h; (b) EMSA showing that the DNA-protein complexes  
between 3  mg MAZ and radiolabelled qhras-1 (10 nM) are competed away by cold G4-decoys 10- and 50-fold in excess compared to 
radiolabelled qhras-1 quadruplex; (c)  Caspase 3/7 assays showing that  in T24 cells active G4-decoys 3, 4,  5 and 6 strongly  activate  
apoptosis. Differences from the control are supported by Student’s t test, P,0.05 (one asterisk), P,0.01 (two asterisks).
doi:10.1371/journal.pone.0024421.g010
It  is  well  known that certain G-rich oligonucleotides  show a 
clear antiproliferative effect in cancer cells which is not due to a 
true  antisense  effect,  but  to  their  propensity  to  fold  into  a  G-
quadruplex [26].  How these oligonucleotides precisely work,  is 
not  yet  clear,  but  Bates  and  co-workers  proposed  that  the 
antiprolif-erative  activity  of  certain  G-rich  oligonucleotides 
requires: nuclease resistance; efficient cellular uptake; binding to 
a specific protein [53]. Our G4-decoys fulfill these requirements 
as: their compact structure and LNA residues make them resistant 
to  nucleases;  they  efficiently  penetrate  cell  membranes  and 
internal-ize  in  the  nucleus  when  complexed  with  PEI;  they 
interact with MAZ, an essential protein for HRAS transcription.
That  our  G4-decoys  act  through  their  binding  to  a  nuclear 
protein  (MAZ)  is  suggested  by  the  fact  that  when  they  are 
delivered  without  a  transfectant  agent,  they  localize  in  the 
cytoplasm and are not active. In contrast, when they are delivered 
with PEI, they reach the nucleus and show a strong antiprolifer-
ative activity.
In accord with the proposed mechanism of action, the decoys 
eliciting the highest inhibition of cell growth (3, 4, 5) caused in 
T24  cancer  cells  a  strong  decrease  of  HRAS  transcript  and 
activation of caspases 3/7.
In  summary,  this  work  shows  that:  G4-DNA  near  the 
transcription start sites of HRAS behaves as a transcription
repressor;  MAZ  and  Sp1  bind  to  G-elements  that  can  fold  into 
quadruplex forming sequences; transcription is activated by MAZ and 
Sp1;  MAZ  destabilized  the  HRAS  G-quadruplexes;  G4-decoys 
mimicking  the  HRAS  quadruplexes  behave  as  decoy  molecules 
against  MAZ  and  cause  a  potent  antiproliferative  effect  in  T24 
bladder cancer cells bearing mutant HRAS; the decoy strategy could 
provide a new therapeutic approach to treat bladder cancer.
Materials and Methods
Plasmids and G4-decoys synthesis
pHRAS-luc was obtained by standard cloning, while mutant plasmids 
pHRAS-mut1, pHRAS-mut2 were obtained by site directed mutagenesis 
with  the  gene  tailor  kit  (Invitrogen).  A  838-bp  Sac  I-Sac  I  fragment, 
obtained from pEJ 6.6 plasmid bearing the human HRAS promoter, was  
cut with Xma I restriction enzyme and the resulting 345 bp fragment was 
subcloned in pGL3–E1 basic plasmid in Sac I-Xma I upstream of firefly 
luciferase. In the resulting construct luciferase was driven by wild-type 
HRAS  promoter  (pHRAS-luc).  By  site  directed  mutagenesis  we 
introduced in pHRAS-luc two point mutations either in hras-1 or hras-2 
sequence. The primers used were 59- CGG GGC CGA GGC CGG TGC 
GGT GCG TGT GCG TGT GC-39 (for) and 59-CCG GCC TCG GCC 
CCG GCC CTG GCC C-39 (rev).
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PCR was performed with 3 ng/ml DNA template, 0.1  mM each primer, 
0.05  units/ml  AccuPrime  pfx  DNA  polymerase  (Invitro-gen)  in  16 
AccuPrime pfx reaction mix for 3 min at 95uC, 30 cycles 1 min at 95uC, 
30 s at 81uC, and 5 min at 68uC. Bacteria DIH 101 5a were transformed 
with  PCR  product,  and  plasmid  DNA  was  extracted  and  sequenced 
(primer pGL3bpr 2 59-CTT TAT GTT TTT GGC GTC TTC CA-39).
Plasmids  pCMV-MAZ  (called  pMAZ),  pCMV-Sp1  (called  pSp1), 
pGEX-MAZ and pGEX-Sp1 have been purchased by RIKEN (Japan).
G4-decoys  were  synthesized  on  an  ExpediteTM  Nucleic  Acid 
Synthesis System Model 8909 from Applied Biosystems. Purifica-tion of 
oligonucleotides was accomplished using a reverse-phase semipreparative 
HPLC  on  Waters  XterraTM  MS  C18  column.  Oligonucleotide 
concentrations were determined by UV-absor-bance at 260 nm, 90uC and 
the  calculated  single-stranded  extinction  coefficients  were  based  on  a 
nearest neighbour model (extinction coefficient for monomers is 22400 at 
260 nm).
CD and DMS footprinting experiments
CD  spectra  have  been  obtained  with  a  JASCO  J-600  spectro-
polarimeter  equipped  with  a  thermostatted  cell  holder,  3  mM 
oligonucleotides in 50 mM Tris–HCl, pH 7.4, 100 mM KCl.
DMS footprinting experiments were performed using PAGE purified 
oligonucleotides,  27-mer hras-1 and h1-mut,  24-mer hras-2 and h2-mut 
(20 nM), end-labelled with [c-32P]ATP (Perkin Elmer) and polynucleotide 
kinase  (New  England  Biolabs,  MA).  Before  the  reactions  they  were 
incubated overnight at 37uC, in 50 mM sodium cacodylate, pH 8, 1  mg 
sonicated salmon sperm DNA, 1 mM EDTA, 100 mM KCl or LiCl or  
CsCl or KCl+TMPyP4 as specified in figure legends. Dimethylsulphate 
(DMS) dissolved in ethanol (DMS:ethanol, 4/1, vol/vol) was added to the  
DNA solution (1 ml to a total volume of 70 ml) and left to react for 5 min 
at room temperature. The reactions were stopped by the addition of 1:4 
volumes  of  stop  solution  (1.5  M  sodium  acetate,  pH  7,  1  M  b-
mercaptoethanol  and  1  mg/ml  tRNA).  DNA  was  precipitated  with  4 
volumes of ethanol and resuspended in piperidine 1 M. After cleavage at 
90uC for 30 min, reactions were stopped with chilling in ice followed by 
precipitation with 0.3 M sodium acetate, pH 5.2 and 3 volumes of ethanol. 
The  DNA samples  were  resuspended  in  90%  formamide  and  50  mM 
EDTA,  denatured  at  90uC  and  run  for  2  h  on  a  denaturing  20% 
polyacrylamide gel, prepared in TBE
   Table 1. RT-PCR primers.
Oligonucleotides 59-39 sequence T, 6C
hHRAS for GGG GCA GTC GCG CCT GTG AA 60
hHRAS rev CCG GCG CCC ACC ACC ACC AG 60
hGAPDHfor CCC TTC ATT GAC CTC AAC TAC ATG 60
hGAPDHrev TGG GAT TTC CAT TGA TGA CAA GC 60
hHPRTfor AGA CTT TGC TTT CCT TGG TCA GG 60
hHPRTrev GTC TGG CTT ATA TCC AAC ACT TCG 60
hb2mglobulinrev CAT TCC TGA AGC TGA CAG CAT TC 60
hb2mglobulinfor TGC TGG ATG ACG TGA GTA AAC C 60
hmazfor CTC CAG TCC CGC TTC T 55
hmazrev GGG AGC AAG TCC ACC T 55
hSp1for CCC TTG AGC TTG TCC CT 50
hSp1rev CCT GTG AAA AGG CAC CA 50
doi:10.1371/journal.pone.0024421.t001
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B = biotin; P = TINA (S4); Underlined bases indicate LNA 
residue. doi:10.1371/journal.pone.0024421.t002
and 8 M urea, pre-equilibrated at 55uC in a Sequi-Gen GT Nucleic Acids 
Electrophoresis  Apparatus  (Bio-Rad,  CA),  which  was  equipped  with  a 
thermocouple that allows a precise temperature control. After running, the 
gel was fixed in a solution containing 10% acetic acid and 10% methanol, 
dried  at  80uC  and  exposed  to  Hyperfilm  MP  (GE  Healthcare)  for 
autoradiography.
Cell culture and proliferation assay
HeLa  and  T24  urinary  bladder  cancer  cells  were  maintained  in 
exponential  growth  in  Dulbecco’s  Modified  Eagle’s  Medium (DMEM) 
containing  100  U/ml  penicillin,  100  mg/ml  strepto-mycin,  20  mM  L-
glutamine  and 10% foetal  bovine  serum (Euroclone,  Milan,  Italy).  For 
proliferative assays T24 cells were seeded (1250 cells/well) the day before 
decoy  treatment  in  a  96-well  plate.  The  G4-decoys,  mixed  to  jetPEI 
(Polyplus  transfec-tion),  were  delivered  to  the  cells  at  increasing 
concentrations up to 800 nM. 48 h after the first delivery a second dose of 
oligonucleotides was given to the cells. 72 h after the second delivery, the 
cell  viability  was  measured  by  resazurin  assays  following  standard 
procedures.
Dual luciferase assays
Firefly luciferase activity in cell lysates was measured and normalized 
for  Renilla  luciferase  activity  using  the  Dual-Glo  Luciferase  Assay 
System  (Promega)  following  vendor’s  instruc-tions.  Transfection  was 
performed by mixing each vector 250 ng/ well with control plasmid pRL-
CMV expressing Renilla luciferase under control  of CMV promoter 10 
ng/well  using  Metafectene  transfection  reagent  (Biontex  Laboratories, 
GmbH)  following  manufacturer  instruction.  For  cotransfection  with 
pMAZ and/or pSp1 100 ng of pHRAS-luc or mutant, with 10 ng of pRL-
CMV, were transfected with either 100 ng of pMAZ/pSp1 or pcDNA3 
plasmid  (empty  vector)  as  mass  for  control  transfections.  Each 
transfection  was  performed  in  triplicate.  Luciferase  assays  were 
performed 48 h after transfection  following instructions.  Samples  were 
read with Turner Luminometer and expressed as Relative luminescence 
(see figure captions).
Recombinant MAZ and Sp1: purification and EMSA
Recombinant  MAZ  and  Sp1  tagged  to  GST  were  expressed  in 
Escherichia coli BL21 DE3 plys using plasmid pGEX-MAZ and
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pGEX-Sp1.  The bacteria  were  grown  for  1–2 h at  37uC to an optical  
density at 600 nm between 0.5–2.0 prior to induction with IPTG (0.2 mM 
final concentration). Cells were allowed to grow overnight at 30uC before 
harvesting. The cells were centrifuged at 5000 rpm, 4uC, the supernatant 
removed  and  the  cells  washed  twice  with  PBS.  The  pellet  was 
resuspended in a solution of PBS with 1 mM PMSF, 1  mM DTT and 
Protease  Inhibitor  Cocktails  (only  for  GST-tagged  proteins)  (Sigma-
Aldrich). The bacteria were lysed by sonication and centrifuged for 30 
min at 4uC, 16000 rpm. Glutathione Sepharose 4B (GE Healthcare) (50% 
slurry in PBS) was added to the supernatant from the previous step and 
incubated for 30 min at 4uC while shaking. The mix was centrifuged for 5 
min at 500 g and the resin was washed 3 times with PBS. Proteins were 
eluted from the resin with a buffer composed by 50 mM Tris-HCl pH 8 
and 10 mM reduced glutathione.
Chromatin immunoprecipitation
HeLa cells  were  plated in  2615 cm diameter  plates,  grown  to  80% 
confluency (about 1.56107 cells) and fixed in formaldehyde 1% in PBS for 
2 or 5 minutes.  Chromatin immunoprecipitation assays were performed 
using the ChIP-ITTM Express kit  (Active Motif,  Rixensart,  Belgium),  as 
previously reported [24]. The antibodies used are MAZ H-50 (sc-28745, 
Santa  Cruz,  Biotech-nology,  Inc),  Sp1  (PEP  2)  (sc-59,  Santa  Cruz, 
Biotechnology, Inc) used at 20 ng/ml. The primers used are: (i) for control 
reaction,  specific for GAPDH (provided by the kit)  that give  a 160 bp 
product;  (ii)  59-GGCTCCTGACAGACGGG  (hras-1for)  and  59-
GCATGGGCTCCGTCC (hras-1rev)  giving a 190 bp product;  (iii)  59-
GGACGGAGCCCATGC  (hras-2for)  and  59-CGTATTGCTGCCGCCT 
(hras-2rev)  giving  a  161  bp  product.  Amplification  products  were 
separated by a 10% acrylamide gel in TBE and visualized with a Gel–
DOC apparatus (Bio-Rad Laboratories, CA, USA).
shRNA transfections, RNA extraction and real-time PCR
Cells  were  seeded  200–400000/well  in  a  24  well  plate.  shRNA 
plasmids  were  transfected  the  day after  plating  0.5  mg/well.  Plasmids 
used  are  shRNA-control,  shRNA-MAZ  and  shRNA-Sp1  (Santa  Cruz 
Biotechnology,  CA,  USA).  Cells  were  collected  48  and  72  h  after 
transfection.
RNA extraction: RNA was extracted using TRIzol reagent (Invitrogen, 
Carlsbad, CA). cDNA synthesis: 5 ml of RNA in DEPC-water was heated 
at 55uC and placed in ice. The solution was added with 7.5 ml of a mix 
containing (final concentrations) 16buffer; 0.01 M DTT (Invitrogen); 1.6 
mM primer  dT [MWG  Biotech,  Ebersberg,  Germany;  d(T)16];  and 1.6 
mM random primers (Promega); 0.4 mM dNTPs solution containing equi-
molar  amounts  of  dATP,  dCTP,  dGTP  and  dTTP (Euroclone,  Pavia, 
Italy); 0.8 U/ml RNAse OUT; 8 U/ml of M-MLV reverse transcriptase 
(Invitrogen). The reactions were incubated for 1 h at 37uC and stopped 
with  heating  at  95uC  for  5  min.  As  a  negative  control  the  reverse 
transcription  reaction  was  per-formed  with  a  sample  containing  DEPC 
water.  Real-time  PCR reactions  were  performed  with  16  iQTM SYBR 
Green  Super-mix  (Bio-Rad  Laboratories,  CA,  USA),  300  nM of  each 
primer,  1  ml  of  RT  reaction.  The  sequences  of  the  primers  used  for 
HRAS, GAPDH, b-2-microglobulin, Hypoxanthine Ribosyl  Transferase, 
MAZ and Sp1 amplifications are reported in Table 1. The PCR cycle was: 
3 min at 95uC, 40 cycles 10 s at 95uC, 30 s at 60uC with an iQ 5 real-time 
PCR  controlled  by  an  Optical  System  software  version  2.0  (Bio-Rad 
Laboratories, CA, USA).
G4-DNA in HRAS Promoter and Decoy Oligonucleotides
Electrophoresis mobility-shift assays
Oligonucleotides  were  end-labelled  with  [c-33P]ATP  and  T4 
polynucleotide  kinase.  Duplexes  hras-1  and  hras-2  were  prepared 
annealing  (10  min  at  95uC,  overnight  at  room temperature)  a  mixture 
containing  1:1,2  ratio  of  radiolabelled  hras-1  or  hras-2  with  the 
complementary  strand  in  50  mM  Tris–HCl,  pH  7.4,  100  mM  NaCl.  
Radiolabelled  hras-1  and  hras-2  were  allowed  to  assume  a  G4-DNA 
structure in 50 mM Tris–HCl, pH 7.4, 100 mM KCl, by heating at 95uC 
and  overnight  incubation  at  37uC.  Before  EMSA,  the  radiolabelled 
oligonucleotides  were  treated  for  30  min  at  room  temperature  with 
different amounts of MAZ or Sp1 (or extract), in 20 mM Tris–HCl, pH 8, 
30 mM KCl, 1.5 mM MgCl2, 1 mM DTT, 8% glycerol, 1% Phosphatase 
Inhibitor Cocktail I (Sigma, Milan, Italy), 5 mM NaF, 1 mM Na3VO4, 2.5 
ng/ml poly [dI-dC]. After incubation, the reaction mixtures were loaded in 
5% TBE (1X) polyacrylamide gel, thermostatted at 20uC. After running, 
the gel was dried and exposed to autoradiography (GE Healthcare, Milan)  
for 24–36 h at 280uC.
FRET-melting experiments
FRET  melting  experiments  were  performed  on  a  real-time  PCR 
apparatus (CFX 96, BioRad, Hercules, CA), using a 96-well plate filled 
with 50 ml solutions of dual-labelled qhras-1 and qhras-2, in 50 mM Tris–
HCl,  pH 7.4,  50  mM KCl  (qhras-1)  or  100 mM NaCl (qhras-2).  The 
protocol,  used  for  the  melting  experiments,  is  the  following:  (i) 
equilibration  step  of  5  min  at  low  temperature  (20uC);  (ii)  stepwise  
increase of the temperature of 1uC/min for 76 cycles to reach 95uC. All 
the samples in the wells were melted in 76 min.
Caspase assays
We  performed  Caspase  activity  assays  using  Apo-ONETM 
Homogeneous  Caspase-3/7  Assay  (Promega),  according  to  the 
manufacturer’s  protocol  using a Microplate  Spectrofluorometer  System 
(Molecular Devices, Concorde, Canada).
Supporting Information
Figure S1 Polymerase stop assays with a wild-type DNA template 
containing hras-1 or hras-2 and a mutant template in which four GRT 
point  mutations  were  introduced  in  sequence  hras-2  to  abrogate 
quadruplex formation. Taq polymerase is arrested at the 39 end of 
hras-2, before the first run of guanines, in keeping with the formation 
of a quadruplex structure by hras-2 (experimental conditions: 37uC, 
140 mM KCl, 50 mM Tris-HCl pH 7.4) When the DNA template is 
incubated with G4-DNA ligands that stabilize quadruplex DNA, Taq 
polymerase is completely arrested and only the truncated product is  
produced. This is observed with porphyrin TMPyP4 and guanidine 
phthalocyanines  DIGP  and  Zn-DIGP  at  r  =  4  (r  =  [ligand]/ 
[template]). Instead, TMPyP2, which does not bind to G4-DNA does 
not affect the processivity of Taq polymerase. When the experiment 
is  performed with  the mutated  template,  Taq polymerase  does not 
stop at the G-element and full product is observed. A longer truncated 
product  is  observed  with  the  mutated  template,  probably due to  a 
hairpin  structure  stabilized  by CG and  GT base  pairs.  Polymerase 
stop  assays  with  a  DNA template  containing  hras-1show that  Taq 
polymerase is arrested in the presence of phthalocyanines, indicating 
that the G-quadruplex formed by hras-1 is less stable than that formed 
by hras-2.(TIF)
Figure S2 CD spectra of the hras-1 and hras-2 mutants. CD spectra in 
50 mM Tris-HCl pH 7.4, 100 mM KCl of hras-1, hras-1
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mut  (59-TCGGGTTGCGGGCGCAGGGCACCTGCG),  hras-2 
and  hras-2  mut  (59-CGAGGCCGGTGCGGTGCGGGGGC-
GGGGGCGCGCGGT).  Cuvette  0.5  cm,  DNA concentration  6 
mM.(TIF)
Figure S3 EMSA showing the binding between recombinant MAZ-
GST and Sp1-GST with duplexes hras-1 and hras-2. (a) radiolabelled 
hras-1 duplex, 15 nM incubated for 30 min with 0, 0.5, 1, 1.5, 2 and 
2.5 mg MAZ-GST; (b) radiolabelled hras-2 duplex, 15 nM incubated 
for  30  min  with  0,  0.5,  1,  1.5,  2  and  2.5  mg  MAZ-GST;  (c) 
radiolabelled hras-2 duplex, 15 nM incubated for 30 min with 0, 0.5, 
1 and 2.5 mg Sp1-GST.(TIF)
Figure  S4  SDS-PAGE  of  eluate  from  Glutathione  Sepharose  4B 
column  loaded  with  protein  extract  of  BL21  bacteria  transformed 
with  a  plasmid  encoding  for  MAZ-GST  or  Sp1-GST  (a)  lane  1: 
bacterial  extract;  lane 2:  proteins that  did not  bind the resin (flow 
through); lane 3, fraction eluted with 10 mM glutathione; (b) lane 1: 
molecular weights; lane 2: bacterial extract; lane 3: proteins that did 
not bind the resin (flow through); lane 4, column wash; lane 5: 1st 
elution  with  10 mM glutathione;  lane  6:  2nd elution  with  10 mM 
glutathione.(TIF)
Figure S5 Silencing in HeLa cells of MAZ and Sp1 by commercial 
shRNAs.  HeLa  cells  have  been treated  with MAZ shRNA or  Sp1 
shRNA complexed  with  Metafectene.  As  control  we treated  HeLa 
cells with control shRNA. MAZ and Sp1 specific shRNA and control 
shRNA have been purchased from Santa Cruz Biotechnology (USA). 
After 48 h, total RNA was extracted, transformed in cDNA and used 
for real-time experiments.  The levels of  MAZ and Sp1 transcripts 
have been measured and reported in graph relatively to the expression 
of  three  housekeep-ing  genes:  GAPDH,  b2-  microglobulin, 
hypoxanthine ribosyl transferase.(TIF)
Figure  S6  (a)  SDS-PAGE  of  fractions  eluted  from  a  Glutathione 
Sepharose 4B column loaded with protein extract obtained from
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Fig. S1: Polymerase stop assay. The formation of G-quadruplexes by hras-1 and hras-2 was 
assessed by polymerase stop assays. We designed two wild-type DNA templates containing 
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hras-1  or  hras-2  and  one  mutant  template  in  which  four  G→T  point  mutations  were 
introduced in hras-2, to abrogate quadruplex formation. Primer-extension reactions showed 
that Taq polymerase was partly arrested at the 3’ end of hras-2, just before the first run of 
guanines,  in  keeping with the formation  of  a  quadruplex  structure  by  hras-2.  Under  the 
experimental condition adopted,  37°C, 140 mM KCl, the polymerase was not completely 
arrested, as the full-length product was present in lane 1. However, when the DNA template 
was incubated with G4-DNA ligands that stabilize quadruplex DNA, Taq polymerase was 
completely arrested and only the truncated product was produced. This was observed with 
porphyrin TMPyP4 and guanidine phthalocyanines DIGP and Zn-DIGP at r=4 (r=[ligand]/
[template]). Instead, TMPyP2, which does not bind to G4-DNA did not affect the processivity 
of Taq polymerase. When the experiment was performed with the mutated template whose 
hras-2  element  cannot  fold  into  a  G-quadruplex  (the  second guanine  in  each block was 
replaced by T), Taq polymerase did not stop at the G-element and full product is observed. A 
longer truncated product is observed with the mutated template, due to a hairpin structure 
stabilized by CG and GT base pairs. Polymerase stop assays were performed also with a 
DNA template containing hras-1. In this case we observed arrest of Taq polymerase in the 
presence of phthalocyanines,  indicating that the G-quadruplex formed by  hras-1 was less 


























































































































Fig. S2: Structure of guanidine phthalocyanines DIGP, Zn-DIGP and porphyrin TMPyP2 used 
in dual luciferase assays
“Tesi di dottorato di Alexandro Membrino, discussa presso l’Università degli Studi di Udine”
MAZ
1  2   3   4   5  6  7
MAZ











Fig. S3:  EMSA showing the binding between recombinant  MAZ-GST and Sp1-GST with 
duplexes hras-1 and hras-2. 


























Fig. S5: Silencing in HeLa cells of MAZ and Sp1 by commercial shRNAs. HeLa cells have 
been treated with MAZ shRNA or Sp1 shRNA complexed with Metafectene. After 48 h, total 
RNA was extracted, transformed in cDNA and used for real-time experiments. The levels of 
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MAZ  and  Sp1  transcripts  have  been  measured  and   reported  in  graph  relatively  to  the 
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Fig. S6: putative structures of the designed G4-decoys. The yellow rectangles represent the 
TINA unit (P).
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Fig. S7: Proliferation assay with T24 cells untreated and treated with 800 nM G4-decoys 3,4,5 
(mimicking   qhras-1)  and  6,7,8 (mimicking  qhras-2).  Decoy 637 is  a  random sequence 
containing one P unit. 
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5. Conclusions
The main  target  of my PhD was to  demonstrate  that  quadruplex DNA has a function on 
transcription. Most laboratories have addressed their efforts to understand why the 5’ end of 
mammalian genes are rich in guanine, while the 3’ end is not. The asymmetric distribution of 
the  guanines  in  the  genome  has  raised  the  hypothesis  that  quadruplex  DNA  should  be 
involved in gene expression regulation either at the promoter or at the transcript level. This 
PhD  work  has  addressed  the  query  whether  quadruplex  DNA  is  an  integral  part  of  the 
mechanism controlling transcription.  To provide an answer we took into consideration the 
HRAS gene, as it possesses upstream of TSS two G-elements composed by runs of guanines 
each folding into a quadruplex structure. Furthermore, HRAS was a good study model because 
the quadruplex-forming sequences overlap the binding site of transcription factors MAZ and 
Sp1.  The  mechanism for  transcription  regulation  that  we  have  proposed is  based  on the 
distinctive observation that MAZ recognizes the  HRAS quadruplexes and unfolds them. So 
MAZ has  a  double function  within  the  HRAS promoter:  a.  unfolds  the quadruplexes  and 
remove the block on transcription and b. activates transcription together with Sp1. Likewise, 
we can  say that  quadruplex  DNA also has  two functions:  a.  inhibits  transcription  and b. 
recruits MAZ to the HRAS promoter when transcription has to be activated.
The molecular strategies that have been proposed to down-regulate transcription in cancer 
cells  may  have  a  potential  in  cancer  therapy.  We  developed  oligonucleotides  decoys 
engineered to be stable in serum. These molecules showed strong antiproliferative effect in 
cancer  at  a  very  low  concentration.  Contrarily  to  other  G-rich  oligonucleotides  whose 
antiproliferative  effect  has  been  correlated  with  their  capacity  to  bind  to  nucleolin,  the 
quadruplex  decoys  proposed  in  this  PhD work behave  with  a  mechanism based on their 
binding to the transcription factors MAZ and Sp1. The good performance of these molecules 
in cancer cell lines allowed us to continue this project by testing the activity of the decoys in  
vivo.  A problem that  should  be  addressed  in  order  to  enhance  the  potency of  the  decoy 
approach is to enhance their cellular uptake using nanotechnologies. 
The second approach consisted in small molecules that easily penetrate the cell membrane and 
bind to the quadruplex. The promoter will be locked in the folded, non active form, inhibiting 
gene  expression.  Guanidinio  phthalocyanines  are  quadruplex  ligands  that  nicely  stabilize 
quadruplex DNA but have a poor access to the nucleus. This strategy will be improved when 
ligands that efficiently penetrate the nucleus will be available.
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